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RESUMO 
Introdução: O cancro da mama é a neoplasia mais frequente e a principal causa de 
morte por cancro nas mulheres em todo o mundo. Aproximadamente 70% dos cancros da 
mama são do subtipo luminal e expressam os recetores de estrogénio. As terapias mais 
comuns e eficazes para as doentes com este subtipo são as terapias endócrinas. No 
entanto, a eficácia destas terapias é limitada, e cerca de 30-40% das mulheres acabam 
por ter recorrência da doença. Uma vez que os microRNAs têm sido associados com 
vários mecanismos de sensibilidade e resistência endócrina, estas moléculas podem 
servir como biomarcadores preditivos e/ou de prognóstico neste subgrupo de doentes.  
Objetivo: O principal objetivo desta dissertação de Mestrado foi investigar se microRNAs 
que estão desregulados em tumores da mama com resistência endócrina podem ser 
clinicamente relevantes como biomarcadores preditivos e de prognóstico em pacientes 
com tumores da mama luminais tratadas com terapia adjuvante endócrina.  
Materiais e Métodos: Começou-se por realizar um ensaio de expressão global com o 
objetivo de identificar microRNAs com expressão diferente entre doentes luminais com e 
sem recidiva da sua doença após o tratamento com terapias adjuvantes endócrinas. 
Posteriormente, sete microRNAs - miR-30b-5p, miR-30c-5p, miR-181a-5p, miR-182-5p, 
miR-196a-5p, miR-200b-3p e miR-205-5p - foram escolhidos para validação num maior 
número de tecidos por RT-qPCR. Seguidamente, o potencial de diagnóstico e de 
prognóstico destes microRNAs foi avaliado através da construção de curvas de ROC e de 
modelos de Regressão de Cox, respetivamente. Realizou-se igualmente análise do status 
de metilação por PCR quantitativo específico em DNA modificado por bissulfito de sódio. 
Por último, analisámos igualmente a expressão de microRNAs em tecidos tumorais 
primários e metástases correspondentes.  
Resultados e Discussão: Após o ensaio de expressão global os microRNAs miR-30b-5p, 
miR-181a-5p, miR-182-5p, miR-196a-5p, miR-200b-3p e miR-205-5p foram selecionados 
para validação, tendo o miR-30c-5p sido utilizado como controlo positivo. A combinação 
dos microRNAs miR-182-5p e miR-200b-3p num painel foi capaz de identificar cancro da 
mama em amostras de tecido com uma acuidade de 95,55%. Adicionalmente, os 
microRNAs miR-30c-5p, miR-30b-5p, miR-182-5p, bem como o miR-200b-5p foram 
identificados como preditores independentes de resposta a terapias endócrinas. Além 
disso, os microRNAs miR-182-5p e miR-200b-3p são marcadores de prognóstico em 
doentes com tumores luminais após tratamento adjuvante com terapias endócrinas. 
Verificou-se ainda que os microRNAs miR-30b-5p e miR-200b-3p estão significativamente 
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mais expressos nas metástases relativamente aos tumores primários correspondentes. 
Além disso, os nossos resultados sugerem que a menor expressão do miR-200b-3p nos 
tumores com resistência à terapia endócrina é dependente de outros mecanismos 
epigenéticos, e não da metilação das suas regiões promotoras.  
Conclusões e perspectivas futuras: Os resultados sugerem que um painel específico 
de microRNAs poderá ser útil na decisão terapêutica em doentes com tumores da mama 
luminais. No entanto, estudos adicionais, idealmente estudos multicêntricos, são 
essenciais para a sua validação. Como principal perspectiva futura, pretendemos avaliar a 
expressão destes microRNAs em biópsias líquidas, de maneira a avaliar o seu potencial 
como biomarcadores não-invasivos.  
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ABSTRACT 
Introduction: Breast cancer is the most frequent malignancy and the leading cause of 
cancer death among women worldwide. Approximately 70% of BrCa are of the luminal 
type, expressing the estrogen receptor. One of the most common and effective adjuvant 
therapies for this BrCa subtype is endocrine therapy. However, its effectiveness is limited, 
with relapse occurring in up to 40% of patients. Because microRNAs have been 
associated with several mechanisms underlying endocrine resistance and sensitivity, they 
may serve as predictive and/or prognostic biomarkers in this setting. 
Aims: The major goal of this master dissertation was to investigate whether miRNAs 
deregulated in endocrine-resistant breast cancer may be clinically relevant as prognostic 
and predictive biomarkers in luminal  
breast cancer patients treated with adjuvant endocrine therapy. 
Material and Methods: We started by performing a global expression assay with the aim 
of identifying microRNAs differentially expressed between luminal patients with or without 
breast cancer recurrence after endocrine therapy. Then, seven microRNAs - miR-30b-5p, 
miR-30c-5p, miR-181a-5p, miR-182-5p, miR-196a-5p, miR-200b-3p e miR-205-5p - were 
chosen for validation using quantitative reverse transcription polymerase chain reaction in 
a larger set of tissue samples. ROC curves and cox-regression models were constructed 
to evaluate miRNAs diagnostic and prognostic performance, respectively. DNA 
methylation analysis was also performed by sodium bisulfite modification followed by 
quantitative methylation-specific polymerase chain reaction. Furthermore, microRNAs 
expression levels were also analyzed in metastatic tissues and the paired primary tumor 
tissue. 
Results and Discussion: From the initial global expression assay, miR-30b-5p, miR-
181a-5p, miR-182-5p, miR-196a-5p, miR-200b-3p and miR-205-5p were selected for 
further validation, and miR-30c-5p was chosen as a positive control. The combination of 
miR-182-5p and miR-200b-3p accurately detects BrCa in tissue samples with an overall 
accuracy of 95.55%. MR-30c-5p, miR-30b-5p, miR-182-5p and miR-200b-5p were found 
to be independent predictors of clinical benefit from endocrine therapy. Moreover, miR-
182-5p and miR-200b-3p displayed independent prognostic value for disease recurrence 
in luminal BrCa patients after endocrine therapy. MiR-200b-3p and miR-30b-5p were 
significantly higher in metastatic tissues when compared to the paired primary tumor 
tissues. Furthermore, our results suggest that miR-200b-3p’s downregulation in endocrine-
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resistant tumors might be dependent on other epigenetic mechanisms rather than DNA 
methylation. 
Conclusions and future perspectives: We concluded that selected miRNAs may 
constitute clinically useful ancillary tools for management of luminal BrCa patients. 
Additional validation, ideally in a multicentric setting, is required to confirm our findings. As 
a future perspective, we intend to assess these miRNAs expression in liquid biopsies in 
order to evaluate their potential as non-invasive biomarkers. 
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Breast Cancer 
Breast Cancer overview 
Epidemiology and Risk Factors 
Breast cancer (BrCa) is the second most common cancer worldwide and the most frequent 
cancer among women (1). In 2012, the estimated age-adjusted annual incidence of BrCa 
in 40 European countries was 92.8/100 000 and the mortality 23.1/100 000 (2). In 
Portugal, BrCa was the leading cancer in 2012 and the first cause of cancer death in 
women (Figure 1) (3). BrCa in males is rare, contributing to ~1% of cases (4).  
 
Figure 1. Estimated Age-Standardized Incidence and Mortality Rates 
(per 100 000) in Portugal in 2012. Adapted from (3). 
BrCa incidence increased after the application of mammography screening and it is still 
increasing with the ageing of the population. On the contrary, due to earlier diagnosis and 
increased treatment with the implementation of adjuvant chemo-, radio- and endocrine-
therapies (ET), the mortality rate has been decreasing in most Western countries, while 
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BrCa prevalence is increasing (3). Indeed, despite the high global incidence, BrCa is the 
fifth cause of death from cancer for both genders. However, it constitutes the leading 
cause of cancer-related deaths in European women and in women worldwide (5, 6). Ten-
year survival of BrCa exceeds 70% in most European regions, being 89% for local and 
62% for regional disease (7). Approximately 5% of patients present with distant metastasis 
at time of diagnosis and 10-15% of patients develop distant metastasis within the first 3 
years (8). Importantly, metastatic BrCa is almost always incurable (9).  
Multiple factors have been associated with an increased risk of developing BrCa with 
distinct scientific evidence (Appendix I); however, it has been estimated that 
approximately 50% of women who develop BrCa have no identifiable risk factors 
excepting increased age and female gender (10). Indeed, BrCa incidence rises sharply 
with age, with the highest rate of BrCa being observed among women aged 75 to 79 (11). 
In addition, BrCa incidence also differs by race and ethnicity (12, 13). For instance, in 
women less than 40 years, BrCa incidence is higher in African-american women than in 
Caucasian women; however, the contrary occurs among those aged 40 years or older 
(12).  
Moreover, some benign breast lesions, e.g., proliferative disease without and with atypia, 
have been associated with a slight increase in the subsequent risk of developing invasive 
BrCa (14). Furthermore, women with a family history of BrCa, especially if the affected 
family member was diagnosed at a younger age, have an increased risk of developing 
BrCa (15). Mutations in the BrCa susceptibility genes BRCA1, DNA repair associated 
(BRCA1) and BRCA2, DNA repair associated (BRCA2) were also associated with a 
significant increase in the lifetime risk of BrCa, that ranges from 26 to 85% (10), however, 
these account for 5 to 10% of all BrCa, and are most strongly related to BrCa occurring in 
younger premenopausal women (16). Additional genes such as Tumor Protein p53 
(TP53), associated with the Li-Fraumeni syndrome (17) and Phosphatase and Tensin 
homolog (PTEN), associated with the Cowden syndrome (18), play a minor role in familial 
BrCa syndromes. 
Many of the established BrCa risk factors can be attributed to some means of elevated 
estrogen exposure, as many studies have consistently demonstrated that increased levels 
of endogenous estrogen are associated with increased BrCa risk in postmenopausal 
women (19), which might be explained by estrogen’s capacity to stimulate proliferation of 
both normal and malignant breast cells (20). Reproductive factors linked to an increase in 
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BrCa risk include early age at menarche and late age at menopause. On the other hand, 
parity and premenopausal oophorectomy have a protective effect on BrCa risk (21). 
Breastfeeding also appears to contribute to a reduced risk of BrCa, although parity may be 
a confounding factor (22). Besides reproductive factors, in postmenopausal women, 
obesity and hormone replacement therapy (HRT) are also associated with increased BrCa 
risk (23).  
There is also a well-established relationship between exposure to ionizing radiation and 
the risk of developing BrCa, with the risk being inversely associated with age at radiation 
exposure (24).  
Finally, there is also a substantial interest in whether dietary or lifestyle factors modify 
BrCa risk. For instance, vegetable consumption and physical activity seem to have a 
moderate protective effect (25), while high-fat diets (26) and alchohol consumption (27) 
seem to be associated with higher rates of BrCa.  
Diagnosis and screening  
The diagnosis of BrCa is initially based on clinical examination, which includes bimanual 
palpation of the breast and locoregional lymph nodes, in combination with imaging (28). 
The current in vivo diagnostic tools for the detection of early-stage BrCa are 
mammography, for which accuracy is greatly affected by age and consequently denser 
breasts (29) and in specific cases magnetic resonance imaging (MRI) (30). A number of 
circulating tumor markers [e.g., carcinoembryonic antigen (CEA) and carbohydrate antigen 
15-3 (CA 15-3)] are sometimes used in the management of BrCa, but due to their low 
sensitivity they are not for screening intent but only for disease monitoring (31). Indeed, 
the presence or absence of carcinoma can only be correctly determined by tissue 
sampling and pathological examination of the primary tumor and cytology/histology of the 
axillary nodes, if involvement is suspected (32). Thus, biopsy remains the standard 
technique for diagnosing both palpable and non-palpable breast abnormalities (32).  
In order to detect BrCa at a pre-clinical stage, several countries have established 
population-based mammography screening programs (33). Mammography screening, 
every 2 years, has shown the greatest mortality reduction benefit in women between 50-69 
years (32). In women with familial BrCa, annual MRI concomitantly or alternating every 6 
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months with mammography, starting 10 years younger than the youngest case in the 
family, is recommended (30).  
Histological subtypes 
BrCa is a highly heterogeneous disease with distinct biological features and clinical 
outcomes. Currently, the World Health Organization (WHO) identifies more than 20 
histological types, using a classification scheme based on the growth pattern and 
cytological features of the tumor cells, and independent of the site of origin in the breast 
(34).   
The majority of BrCa has origin at epithelial cells and can be subdivided into in situ and 
invasive carcinomas. In situ carcinomas might be lobular carcinoma in situ (LCIS) or 
ductal carcinoma in situ (DCIS), and are defined as pre-invasive lesions in which 
neoplastic epithelial cells proliferate confined to the ductal/lobular tree of the breast without 
evidence of invasion through the basement membrane (35). DCIS is more frequent than 
LCIS and, with the implementation of mammographic screening programs, represents 
about 20-25% of newly diagnoses BrCa (34, 35). Invasive carcinomas are the most 
common lesions, representing 70-80% of all BrCa malignant neoplasms (35). Invasive 
carcinomas can generally be grouped in two categories: invasive carcinoma of no special 
type (NST), also known as invasive ductal carcinoma (IDC), and special subtypes 
carcinomas (SSC), with IDC representing up to 75% of all invasive carcinomas (34). The 
most common lesion of the SSC group is the invasive lobular carcinoma (ILC), 
representing 5-15% of all BrCa. Tumors that have both SSC pattern (10-49%) and NST 
pattern are categorized as mixed (34).  
Prognostic and predictive biomarkers 
A prognostic factor is defined as a measurement taken at the time of diagnosis or surgery 
that is associated with the innate aggressiveness of untreated BrCa and thus outcome, 
while a predictive factor is a measurement that predicts response or lack of response to a 
specific treatment (10). In clinical practice, many biomarkers have both prognostic and 
predictive significance.  
Histologic grade, determined by using the Nottingham combined histologic grade proposed 
by Elston and Ellis (Appendix II), has been shown to have prognostic significance and is a 
key component for clinical decision-making (34, 36). Moreover, the Tumor, Node and 
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Metastases (TNM) staging system published by the American Joint Committee on Cancer 
(AJCC)/Union for International Cancer Control (UICC) is based on established clinical and 
pathological prognostic factors, namely tumor size (T), the extent of axillary lymph node 
involvement (N) and the spread of distant metastases (M) (34) (Appendix III). This staging 
system allows the establishment of five stages in order to evaluate the disease extension 
and the patient’s prognosis (Appendix IV).   
However, grade and stage display limited value as sole prognostic factors and other 
prognostic and therapy predictive biomarkers have been introduced in the daily practice 
(32). Indeed, estrogen receptor (ER), progesterone receptor (PR) and human 
epidermal growth factor 2 receptor (HER2) status assessed by immunohistochemistry 
are also evaluated in all breast tumors.  
ER and PR are two nuclear transcription factors activated by the hormones estrogen and 
progesterone, respectively, and are the most important and useful predictive factors 
currently available. Indeed, ER expression is a strong ET predictive marker of response 
(34, 37). Besides, PR-negative patients have a higher relative risk of disease recurrence 
after ET in comparison to patients with PR-positive tumors. Moreover, ER-negative tumors 
have a poorer prognosis in the first years after diagnosis, but after 5 to 10 years ER-
positive tumors have the poorer outcome (38). Importantly, BrCa may relapse in ER-
positive patients more than 20 years after the diagnosis (39).  
HER2 gene is an oncogene localized in the chromosome 17 and is amplified in  
approximately 15% of BrCa tumors yielding overexpression of its coding protein, a growth 
factor receptor present in breast epithelial cell surface (40). HER2 status has both 
prognostic and predictive significance. Although HER2-positive BrCa patients have a 
worse prognosis, HER2 positivity is predictive of a favorable response to HER2-targeted 
therapy (e.g. trastuzumab) (34, 37). In addition, HER2 positivity is also a response 
predictor of anthracycline- and taxane-based therapy (41) and of unresponsiveness to ETs 
(42).  
Proliferation markers such as the Ki-67 may supply additional useful prognostic 
information (43). Furthermore, patient age has been consistently shown to be a prognostic 
factor, as very young BrCa patients have a poorer prognosis than older patients (10). 
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Nonetheless, clinical decisions based upon one or small number of genes or their coding 
proteins in the tumor tissue have failed to predict patients’ outcome, which prompt to the 
development of  other prognostic assays, based in the examination of multiple expressed 
genes, e.g., Oncotype DX [21‑gene derived recurrence score (RS)], MammaPrint 
(Amsterdam 70‑gene derived RS) and PAM50 (50‑gene derived RS) (44), for both 
classification and prognostication of individual tumors. However, widespread use of gene-
expression profiling in clinical practice remains limited, primarily due to the high costs 
and technical difficulty encountered when carrying out high-throughput gene-expression 
profiling, in addition to the invasive diagnostic procedures, since tissue biopsies are 
required.  
Molecular Subtypes 
Based on gene expression profiling, BrCa is often classified into four well-established 
intrinsic subtypes (Table 1), which are associated with distinct biological features and 
clinical outcomes (45, 46). These intrinsic subtypes can be defined by gene expression 
profiling using multiparameter molecular tests such as the PAM-50 (47, 48). Luminal 
tumors typically express luminal cytokeratins (CK) 8 and 18 (44). Luminal tumors can be 
further subdivided into Luminal A and Luminal B. The major molecular distinctions 
between luminal A and B tumors are based in the ER‑related genes’ higher expression in 
luminal A tumors, whereas luminal B tumors exhibit a higher expression of 
proliferation‑related genes (49). ER-negative tumors encompass two subtypes:  the HER2-
enriched subtype, characterized by high expression of several genes in the HER2 
amplicon at 17q22.24, including HER2 (48) and the basal-like subtype, characterized by 
CK 5/6 and CK17 and basal epithelial genes’ expression (48). 
However, due to financial constraints, surrogate approaches have been developed for 
routine clinical practice using more widely available immunohistochemistry (IHC) assays 
for ER, PR and Ki-67 index, together with IHC and/or in situ hybridization for HER 
overexpression/amplification (32). Luminal A tumors do not overexpress HER2 and have a 
low Ki-67 index, while luminal B tumors can be HER2 negative or positive. Commonly, 
Luminal B negative for HER2 expression has either high Ki-67 value or a negative or low 
PR expression. Eighty % of Basal-like tumors overlap with triple-negative tumors, negative 
for both hormone-receptors and HER2 expression (50) (Table 1).  
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These subtypes contribute to insights into cancer initiation and progression and might be 
of value in assessing prognosis and prediction response to therapy, guiding clinical 
management (32, 51, 52).  
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Table 1. Breast Cancer molecular subtypes characterization (1, 30, 32, 48, 49, 53-57). 
Breast cancer 
subtypes 
Clinicopathological 
surrogate markers 
Incidence 
(%) 
Signature genes 
Prognosis 
[5/10-year survival rate (%)] 
Adjuvant 
therapeutic 
options 
Luminal A 
ER
+
 
PR high * 
HER2
- 
Ki-67 low ** 
50-60 
ESR1 and/or PGR, KRT8/18, 
GATA3, XBP1, FOXA1 and 
ADH1B 
Show the most favorable 
clinical features in the first 
years of follow-up 
[95/85] 
ET alone in the 
majority of cases 
+ Cht if high 
tumor burden 
(≥N3, ≥T3) 
Luminal B 
HER2
-
 
ER
+ 
HER2
-
 
Ki-67 high or PR low 
10-20 
ESR1 and/or PGR, KRT8/18, 
FGFR1, ERBB1, MKI67 
and/or CCNE1, CCNB1 and 
MYBL2 
Show less favorable clinical 
outcomes compared with 
luminal A tumors 
[80/75] 
ET + Cht for the 
majority of cases 
HER2
+
 
ER
+
 
HER2
+
 
Any Ki-67 
Any PR 
ChT + anti-
HER2 + ET for 
all patients 
Basal-like 
ER
-
 
PR
-
 
HER2
-
 
10-20 
KRT5/6, KRT17, ERBB1 
and/or KIT, FOXC1, TP63, 
CDH3, VIM and LAM 
Poor clinical features and 
survival 
[75/70] 
ChT 
HER2-enriched 
HER2
+ 
ER
-
 
PR
-
 
10-15 ERBB2 and GRB7 
Poor clinical features and 
survival 
[65/60] 
ChT + anti-
HER2 
* Suggested cut-off value is 20% (32) ** Ki-67 scores should be interpreted in the light of local laboratory median values (32) 
Abbreviations: ER – estrogen receptor; PR – progesterone receptor; HER2 - Human Epidermal growth factor Receptor 2; ESR1 - Estrogen 
Receptor 1; PGR - Progesterone Receptor; KRT – keratin; ; GATA3 - GATA Binding Protein 3; XBP1 - X-Box Binding Protein 1; FOX - Forkhead Box; 
ADH1B - Alcohol Dehydrogenase 1B (Class I), Beta Polypeptide; FGFR1 - Fibroblast Growth Factor Receptor 1; ERBB - Erb-B2 Receptor Tyrosine 
Kinase; MKI67  - Marker Of Proliferation Ki-67; CCN – Cyclin; MYBL2 - MYB Proto-Oncogene Like 2; MYBL2 - MYB Proto-Oncogene Like 2; KIT - 
KIT Proto-Oncogene Receptor Tyrosine Kinase; TP63 - Tumor Protein P63; CDH – Cadherin; VIM – vimentin; LAM – laminin; GRB7 - Growth Factor 
Receptor Bound Protein 7; Cht – chemotherapy.
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Therapeutic approaches 
Currently, several treatment strategies available for BrCa patients are based on the tumor 
burden/localization and biology, as well as age, general health status and patient’s 
preferences (58). Indeed, BrCa is the pioneer of personalized medicine in oncology.  
Neoadjuvant treatment might be performed in multifocal disease, or in order to downsize 
locally advanced and large unifocal unresectable primary tumors that would require 
mastectomy (58). All modalities that will be described for adjuvant systemic treatment 
might also be used as neoadjuvant therapy. 
Regarding local treatment, breast-conserving surgery is amenable in the vast majority of 
newly diagnosed cancers, while mastectomy is carried out for larger tumor sizes, tumor 
multicentricity, inability to achieve negative surgical margins after multiple resections, prior 
radiation to the chest wall/breast or other contraindications to radiotherapy (RT) or even 
when patient demands (59). The treatment of regional lymph nodes can be performed 
using two approaches: axillary clearance and sentinel lymph node biopsy (SLNB). 
Presently, SLNB is the standard care for axillary staging in early, clinically-negative BrCa, 
due to the associated reduced morbidity (60). Conventional axillary lymph node clearance 
is mandatory in the presence of macrometastatic spread in the sentinel node (61). After 
breast-conserving surgery and after mastectomy in node-positive patients RT is highly 
recommended (62, 63).  
Adjuvant systemic therapy, to prevent BrCa recurrence by eradicating micrometastatic 
tumor deposits present at diagnosis, comprises three modalities: chemotherapy, anti-
HER2 therapy (trastuzumab) and ET.  
Most luminal A tumors, except those with the highest risk of relapse, do not require 
adjuvant chemotherapy, whereas most luminal B tumors, especially those with HER2 
overexpression, benefit from this modality (64). Triple-negative tumors and HER2-
overexpressing tumors benefit from this systemic therapy. HER2-positive patients are also 
treated with a monoclonal antibody that interferes with HER2 (e.g. trastuzumab) (64). 
ET, which blocks ER activation, is indicated for all ER-positive patients to stop or slow the 
growth of hormone-sensitive BrCa (58). ETs include: selective ER modulators (SERMS), 
such as tamoxifen, which competes with the estrogen hormone estradiol (E2) for binding 
ER and inhibit ER transcriptional activity in BrCa cells by recruiting corepressors; selective 
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SER down-regulators (SERDs), such as fulvestrant, that in addition to binding to ER also 
stimulate its degradation; and aromatase inhibitors (AIs), such as  letrozole (non-
steroidal/reversible inhibitor) and exemestane (steroidal/reversible inhibitor) that suppress 
estrogen production in adipose tissue and other peripheral tissues by blocking the activity 
of the aromatase enzyme that synthesis estrogen via aromatization of androgens. Ovarian 
suppression with the use of gonadotropin-releasing hormone (GnRH) agonists or ovarian 
ablation remains controversial (65),  and GnRH agonists should only be used as an 
alternative to cyclophosphamide/methotrexate/fluorouracil-type chemotherapy when this 
treatment is not tolerated (66) or in patients with contraindications to tamoxifen (32). The 
choice of the agent is primarily determined by patients’ menopausal status, being AI 
therapy recommended for postmenopausal women, while in premenopausal women 
tamoxifen (5-10 years) is the standard ET (67, 68).  
Although ET results in substantial improvement of patients’ outcome, treatment resistance 
has become a major limitation (49), affecting 30-40% of ER-positive BrCa patients, with all 
those treated in the metastatic setting eventually progressing (69). Among the luminal 
subtype, luminal A tumors display the best clinical outcomes after ET.  
Endocrine Resistance 
According to 3rd ESO–ESMO International Consensus Guidelines, endocrine resistance 
may be defined as primary endocrine resistance when patients relapse within the first 2 
years of adjuvant ET, or as secondary (acquired) endocrine resistance, when patients 
relapse while on adjuvant ET after the first 2 years of treatment or within the 12 months 
after completing treatment (70). Detailed information on the biology of the several 
molecules implicated in endocrine resistance in vitro and the means by which they cause 
resistance is summarized in several recent reviews (71-75).  
As mentioned before, ER expression is currently the most important ET response 
biomarker and altered ER expression contributes to the development of endocrine 
resistance (76). However, ER has been found to be absent in only 15-20% of endocrine-
resistant cancers, implicating other mechanisms in the development of endocrine-
resistance (77). 
ER may have a genomic or a non-genomic signaling. Genomic ER signaling includes the 
classic mode of estrogen signaling, in which E2 binds to ER inducing a conformation 
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change that leads to its activation and binding to DNA sequences denominated estrogen 
response elements (ERE). Alternatively, the E2-ER complex may  interact with other 
transcription factors to facilitate their binding to serum response elements (SREs) and the 
activation of transcription (78). Ligand-independent ER activation has been shown to play 
a role in endocrine resistance, and may be caused, for example, by mitogen-activated 
protein kinase (MAPK) and protein kinase B (Akt) phosphorylation (79). Furthermore, 
increased ER splice variants’ expression, e.g., ERα36, has also been linked to endocrine 
resistance (80, 81).  
A small percentage of ER is localized at the plasma membrane and E2 binding to these 
receptors mediates a non-genomic ER signaling by initiating rapid intracellular 
phosphorylation cascades’ activation mediated by phosphoinositide3-kinase (PI3K) or Akt 
(82, 83). Indeed, several mechanisms of endocrine resistance include amplification or 
abnormal activation of multiple growth factor signaling pathways (84), including HER2 (85), 
MAPK (86) and PI3K (87). In some cases, deregulation of these signaling pathways 
occurs as a result of genetic or epigenetic modifications (88), whereas in other cases, 
deregulation reflects aberrations in upstream regulators, such as the activation of Akt in 
association with the loss of PTEN expression (89, 90).  
In addition to the deregulation of estrogen signaling, unrelated mechanisms that endows 
tumor cells with alternative proliferative and survival stimuli, e.g. disturbances in the 
apoptosis pathways, might also play a significant role in endocrine resistance (91). 
Besides, a link between epithelial-to-mesenchymal transition (EMT) and endocrine 
resistance has already been reported in BrCa (92, 93). 
Epigenetics 
The concept of epigenetic has been evolving through the years, and currently is defined as 
the study of mechanisms that initiate and maintain patterns of gene function and regulation 
without affecting the nucleotide sequence, in a heritable manner (94). The potential role of 
epigenetic processes to complement genetic changes in cancer has been already 
accepted. Indeed, epigenetic aberrations arise early in the carcinogenesis process and are 
therefore potential targets for early detection (94). In addition, epigenetic alterations may 
be reversed by drugs, providing the opportunity to design epigenetic therapies (95). Four 
different mechanisms of gene expression regulation are comprised in the field of 
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epigenetics, namely: DNA methylation, covalent histone modifications, histone variants 
and non-coding RNAs (ncRNAs) (94).  
DNA methylation 
DNA methylation commonly occurs with the addition of a methyl group at the 5’ position of 
a cytosine ring inside CpG dinucleotides (96, 97). CpG sites are concentrated at 5’-gene 
regulatory regions, denominated CpG islands, which are characterized by having 200 or 
plus base pairs (bp), CG content of at least 50% and a ratio of observed/expected CpG 
frequency of at least 0.6 (98, 99). About 60% of human gene promoters contain a CpG 
island, which are usually unmethylated in normal cells (98, 100). DNA methylation is 
performed by specific enzymes denominated DNA methyltransferases (DNMTs), either by 
de novo (DNMT3A and DNMT3B) or for the maintenance of methylation (DNMT1) (98, 99). 
This epigenetic alteration may be removed through demethylation, which can take place 
as a passive process due to the impairment of DNA methylation maintenance or as an 
active mechanism that remains controversial (101, 102).  
DNA methylation is responsible for gene expression inhibition, directly by avoiding the 
binding of transcription factors and/or indirectly by recruiting methyl-CpG binding domain 
(MBC) proteins, which in turn promote the recruitment of histone modifying and chromatin-
remodeling complexes that lead to repressive states of chromatin organization (97, 98).  
Several studies throughout the last two decades have been showing the DNA methylation 
deregulation in cancer (103). Indeed, tumor cells are characterized by a global loss of DNA 
methylation and also by hypermethylation at specific CpG islands, especially in promoter 
regions of tumor-suppressor genes (95, 98). In BrCa, several genes have been identified 
as being hypermethylated, including genes coding metabolic enzymes [e.g. Glutathione S-
Transferase Pi 1 (GSTP1)] and cell cycle inhibitor genes [e.g. Ras Association Domain 
Family Member 1 (RASSF1A)] (104).  
Covalent histone modifications and histone variants 
The basic units of chromatin are nucleosomes, core particles that consist of about 147 bp 
of DNA wrapped around an octamer consisting of two copies of each core histones - H2A, 
H2B, H3 and H4 - and a molecule of histone H1 that seals the two turns of DNA (105). 
Chromatin is not a static construction, but varies between two different states: 
heterochromatin, a highly packaged conformation that commonly contains  inactivate 
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genes; and euchromatin, a more relaxed form associated with an active transcription 
(106).  
Histone proteins present an unstructured N-terminal tail that may undergo post-
translation modifications, which affect the chromatin structure (105, 107, 108). The most 
well-known modifications are histone acetylation and histone methylation. Histone 
acetylation is performed by a family of enzymes denominated histone acetyltransferases 
(HATs), and histone deacetylation is performed by histone deacetylases (HDACs) (108). 
Acetylation occurs in lysines and leads to the promotion of gene expression (105). Histone 
methylation, in turn, can occur in lysine (mono-, di- or trimethylation) or arginine (mono- or 
di-methylation) residues, leading either to transcription repressing or gene activation (105). 
Histone methyltransferases (HMTs), responsible for the addition of methyl groups to 
residues, and histone demethylases (HDMs) that can reverse such change, are the two 
families of enzymes that control histone methylation. The various histone modifications are 
interpreted by other proteins termed “readers”, which modify local chromatin structure to 
either stimulate or repress gene expression (108).  
Post-translation modifications of histone tails have also been found deregulated in several 
cancers, including BrCa (109). For instance, Enhancer of zeste 2 (EZH2), a 
methyltransferase responsible for the H3K27me3 mark, is found overexpressed in BrCa 
and correlates with poorer prognosis of BrCa patients (110).  
Histone variants are non-allelic variants of the major histones that are key players in 
shaping chromatin structure and, when deregulated, may contribute to cancer initiation 
and progression (111). For instance, a direct role for H2A.Z in cancer was found in 
hormone-dependent breast, where an elevated level of H2A.Z expression significantly 
associated with metastasis to lymph node and with shorts overall survival (OS) (111-113) 
Non-coding RNAs  
The most-well studied sequences in the human genome are those of protein-coding 
genes, which comprises only 2% of the human genome. However, about 90% of the 
human genome is transcribed into RNA molecules (114). In the last years, it has become 
increasingly apparent that the non-protein-coding portion of the genome is of crucial 
importance, and particular emphasis has been given to ncRNAs. NcRNAs are composed 
of different classes depending on their size, interactions and activity, including some well-
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known RNAs such as transfer RNAs (tRNAs), ribosomal RNAs (rRNAs) and small 
nucleolar RNAs (snoRNAs), as well as microRNAs (miRNAs) and long non-coding RNAs 
(lncRNAs) (31). 
As expected by their functional importance within cellular context, ncRNAs are deregulated 
in human diseases, including cancer (114, 115). Indeed, new potential diagnostic, 
prognostic and predictive biomarkers, as well as therapeutic targets, have been emerging 
since the established role of ncRNAs in disease onset and development (116). MiRNAs 
involvement in cancer has been the most studied throughout the last years (114).  
MicroRNAs 
MiRNAs are a class of small [~22 nucleotides (nt)] non-coding single-stranded RNAs first 
discovered in Caenorhabditis elegans, in 1993 (117). MiRNAs have important roles in a 
wide range of biological processes at posttranscriptional level (118). Indeed, computational 
predictions estimate that each miRNA regulates hundreds of different messenger RNAs 
(mRNAs) and about 50% of the human transcriptome is subject to miRNA regulation (119).  
Biogenesis and mode of action 
MiRNAs genes are found dispersed across the genome either as single genes or in gene 
clusters that give rise to polycistronic transcripts from which the individual miRNAs are 
processed. MiRNAs genes may be located in intergenic regions or in transcription units in 
either sense or antisense orientation (Figure 2) (120). MiRNAs localized within introns 
have been denominated “mirtrons” (121). Besides, miRNAs may be transcribed from their 
own promotor, or be co-transcribed with the host gene in which they reside (120)..  
MiRNAs pass through a long maturation process that begins in the nucleus and ends in 
the cytoplasm (Figure 2). Briefly, in the standard (canonical) miRNA biogenesis pathway, 
miRNAs genes are transcribed by RNA polymerase II, generating a large miRNA 
precursor (primary-miRNA) which contains one or more stem-loops or hairpin structures 
that are recognized and cleaved by the nuclear microprocessor complex consisting of the 
endonuclease Drosha and the Di-George syndrome critical region gene 8 (DGCR8) 
protein, originating an RNA hairpin intermediate (pre-miRNA) with two nt 3’ overhang 
(122). In turn, mirtrons seem to follow an alternative biogenesis pathway, being processed 
by the splicing machinery and originating debranched introns that mimic the structural 
features of precursor miRNAs without Drosha-mediated cleavage (123). From this point 
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on, canonical and alternative mechanisms merge following a common pathway. The pre-
miRNA is actively transported from the nucleus to the cytoplasm through the Exportin-5 
(XPO5), where it is cleaved by the endonuclease Dicer together with the trans-activation 
response RNA binding protein (TRBP), yielding a transitory miRNA duplex (118). 
Supported by the HSC70-HSP90 chaperone machinery, this duplex is loaded into an 
Argonaute (AGO) protein as a dsRNA and subsequent maturation steps expel one of the 
miRNA duplex strands, producing a mature RNA-induced silencing complex (RISC) (124).  
 
Figure 2. MiRNA biogenesis pathway: canonical and alternative pathway, from nucleus to cytoplasm. 
Abbreviations: miRNA – microRNA; POL – polymerase; DGCR8 - Di-George syndrome critical region gene 8; 
Ldbr - lariat debranching enzyme; GTP - Guanosine-5'-triphosphate; TRBP - Trans-activation response RNA 
binding protein; HSP - Heat shock proteins; UTR - untranslated region; RISC - RNA-induced silencing 
complex; AGO – Argonaute; Ran - RAs-related Nuclear protein. Amorim, Maria unpublished.  
MiRNAs targets are identified through base-paring interactions between a 6-8 nt domain at 
the 5’ end of the loaded miRNA, denominated “seed sequence”, and an mRNA target 
[generally the 3’ untranslated regions (UTR)]. MiRNAs can downregulate gene expression 
by either two posttranscriptional mechanisms: mRNA cleavage when the mRNA has 
perfect complementarity to the miRNA, or translational repression, when the 
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complementary between the miRNA and the mRNA is only partial (119). Initially, miRNAs 
binding sites were thought to be exclusively located in the 3’UTR of target mRNAs. 
Recently, 5’-UTR and open reading frames (ORF) were reported as containing target 
sequences for miRNAs function, increasing the complexity degree in miRNAs’ research 
filed (125, 126). Indeed, miRNAs binding to the 5’UTR seems to upregulate the target 
mRNA translation (127). Recently, the so-called P-bodies were singled out as sites where 
translational repression occurs. Target mRNAs were found to be sequestered in the 
cytoplasmatic P-bodies away from the ribosomes thereby precluding their translation 
(128).  
MicroRNAs deregulation in cancer 
MiRNAs are known to play a significant role in cellular transformation and carcinogenesis, 
and several studies have been showing a differential miRNA expression profile and a 
global miRNA downregulation in human malignancies as compared with normal (129).  
Many changes occur in cancer cells that might influence, in a direct or indirect manner, 
miRNA expression, e.g. genomic rearrangements and abnormalities in miRNA processing 
genes or proteins (130, 131). Besides, recent studies have suggested that disrupted 
epigenetic alterations may also be involved in the dysregulation of miRNAs, particularly 
abnormal DNA methylation of CpG islands in the miRNAs promoter regions (131-133). 
Indeed, a comprehensive bioinformatics analysis found that about 50% of miRNA genes 
are associated with CpG islands, suggesting that several miRNAs might be candidate 
targets of the DNA methylation machinery (14). 
Figure 3 exemplifies some of the miRNAs that are associated with the carcinogenesis 
process, and some of the target genes through which they exert their regulatory function 
(129). Indeed, the aberrant miRNA expression in human tumors is not just a casual 
association, but they can exert a causal role, as oncogenes (oncomiRs) or tumor 
suppressors, in different steps of the tumorigenic process. OncomiRs act by repressing 
the expression of tumor suppressor genes and are frequently upregulated in cancer. 
Tumor suppressor miRNAs act by targeting oncogenes and are frequently 
downregulated in cancer (129). However, this miRNA categorization may be inaccurate, as 
many studies have shown that miRNAs may present a dual function, with oncogenic or 
tumor suppressive properties based on tumor type and cellular context (134). 
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Figure 3. Examples of oncomiRs and tumor suppressor miRs associated with the carcinogenesis process, and 
some of the target genes through which they exert their regulatory function. Abbreviations: MYC – MYC 
proto-oncogene, bHLH transcription factor;  E2F – Transcription factor E2F/dimerisation partner family protein; 
PTEN – Phosphatase and tensin homolog; CDKN – Cyclin-dependent kinase inhibitor PRKAA1 – Protein 
kinase AMP-activated catalytic subunit alpha 1; TP53INP1 - Tumor Protein P53 Inducible Nuclear Protein 1; 
INPP5D – Inositol polyphosphate-5-phosphatase D; TPM1 – Tropomyosin 1; PDCD4 – Programmed cell death 
4; CDKN1B – Cyclin dependent kinase inhibitor 1B; PI3KR1 – Phosphoinositide-3-Kinase Regulatory Subunit 
1; LATS2 – Large tumor suppressor kinase 2; CDK – Cyclin-dependent kinase; CCNA1 - Cyclin A1;  ABL1 – 
ABL proto-oncogene 1, non-receptor tyrosine kinase; SOX2 – SRY-box 2; KLF4 – Kruppel like factor 4; TCL1A 
– T-cell leukemia/lymphoma 1A; DNMT – DNA methyltransferase; IGFBP2 – insulin like growth factor binding 
protein 2; MERKT – MER proto-oncogene, tyrosine kinase; RHOA – ras homolog family member A; BCL2 – 
BCL2, apoptosis regulator; CCN – cyclin; E2F3 – E2F transcription factor 3; TNFRSF6B – TNF Receptor 
Superfamily Member 6b; KRAS – KRAS proto-oncogene, GTPase; HMGA2 – high mobility group AT-hook 2; 
Amorim, Maria unpublished. 
MicroRNAs and their use in the clinic 
In recent years, miRNAs have been implicated in the clinical management of cancers at 
every stage (135). Firstly, miRNA expression profiles can be used as a diagnostic tool, 
since each tumor type seems to have a distinct miRNA signature that distinguishes it from 
normal tissues and other cancer type (136-138).  Secondly, prognostic miRNA 
expression signatures may be identified within tumor groups (139-141). Thirdly, miRNAs 
may also function as predictive biomarkers, helping clinicians in the choice of the correct 
individual therapeutic approach (142). Lastly, miRNAs may be targets of cancer 
therapeutic intervention, either by inducing or re-expressing tumor suppressor miRNAs, 
or by downregulating oncomiRs (143).  
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In addition to offering an attractive option as stable biomarkers in the tumor tissues [e.g. 
formalin-fixed paraffin-embedded (FFPE) blocks and fresh frozen tissues], the use of 
circulating miRNAs as biomarkers is also possible, since tumor cells can release miRNAs 
stabilized by their incorporation into microvesicles or associated with protein complexes , 
which have shown stability in several bodily fluids (e.g. plasma, serum and urine) (144). 
MicroRNAs and Breast Cancer 
Amorim, Maria, et al. "Decoding the usefulness of non-coding RNAs as breast cancer 
markers." Journal of translational medicine 14.1 (2016): 265 (Appendix V).  
MiRNAs and endocrine resistance 
In recent years, several studies have been linking miRNAs deregulation with endocrine 
resistance (145-148). Some of the miRNAs identified are depicted in Figure 4 along with 
their putative targets and functional implications. 
 
Figure 4. MiRNAs and their established targets involved in endocrine resistance. The miRNAs and their 
targets involved in several mechanisms associated with endocrine resistance, along with their functional 
implication (in pink boxes), including loss of/reduced ESR1 expression, alternative growth factors signaling, 
including PI3K/Akt and MAPK signaling pathways, dysregulation of cell survival and apoptosis pathways, and 
increased metastasis. MiRNAs that confer sensitivity and resistance to endocrine therapies are depicted in 
gree and red, respectively. Abbreviations: ER – estrogen receptor; HER2 - Human Epidermal growth factor 
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Receptor 2; EGFR - epidermal growth factor receptor; IGFR1 - insulin-like growth factor 1 receptor; YWHAZ  - 
Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Zeta; MTDH – metadherin; 
MAGI2 - membrane-associated guanylate kinase inverted 2; PTEN - Phosphatase and tensin homolog; EMT - 
epithelial–mesenchymal transition; CDKN - Cyclin-dependent kinase inhibitor; CDK3 - cyclin dependent kinase 
3; BCL2 - BCL2, apoptosis regulator; PI3K/AKT - phosphoinositide 3-kinase/Protein kinase B; ESR1 - estrogen 
receptor 1; TMX – Tamoxifen; AIs – aromatase inhibitors; E2 – Estradiol; miR – microRNA; miR-200f – miR-
200 family. Amorim, Maria unpublished. 
For instance, whereas decreased ER expression and endocrine resistance may be due to 
miR-221/222 overexpression (149, 150), miR-342-3p expression is positively correlated 
with ER mRNA transcript levels, being downregulated in tamoxifen refractory BrCa (151). 
MiRNAs have also been implicated in altering post-translational ER modifications. For 
instance, miR-873 directly targets the cyclin dependent kinase 3 (CDK3) transcript that 
phosphorylates ER inducing its ligand independent activation, and the downregulation of 
miR-873 has been identified in endocrine resistant BrCa cell lines (152). 
Furthermore, miRNAs regulating BrCa cells’ growth, survival and apoptosis may also be 
implicated in loss of responsiveness to ET by endowing tumor cells with alternative 
proliferative and survival stimuli (91). Indeed, miR-519a associated with worse prognosis 
In luminal BrCa patients, directly targeting the transcripts of cyclin dependent kinase 
inhibitor 1A (CDKN1A) and PTEN, allowing for enhanced signaling of the PI3K growth and 
survival pathway (153).  
Furthermore, miRNA-mediated endocrine resistance might be related with EMT and BrCa 
cells metastatic potential, as miR-200 family (miR-200f) members were found 
downregulated in endocrine-resistant BrCa vs. endocrine-sensitive cell lines, acting as 
major regulators of EMT (154, 155). 
Table 2 summarizes some of the miRNAs involved in endocrine resistance/sensitivity, 
along with their putative targets and biological samples in which they were studied. 
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Table 2. Non-coding RNAs involved in response (sensitivity/resistance) to endocrine therapies along with their 
putative targets/mechanism. 
ET Role  miRNA Putative target Agent Samples Refs. 
AntiE 
S 
miR-375 MTDH 
TMX 
Cell lines 
(156) 
miR-873 CDK3 (152) 
miR-320a ARPP19, ESRRG   (157) 
Let-7b/i 
ESR1 
(ER-α36 variant) 
(158) 
miR-451 YWHAZ (159) 
miR-17/20 CCND1 (160) 
miR-148a 
miR-152 
ALCAM (161) 
miR-200c/b ZEB1/2 
TMX and 
FULV 
(155) 
miR-15a/16 BCL2 
TMX 
Cell lines and 
xenografts 
(162) 
miR-342-3p BMP7, GEMIN4 
Cell lines and tumor 
tissues 
(151) 
miR-26a EZH2  
Tumor tissues 
(163) 
miR-30c EGFR (146) 
miR-10a  
miR-126 
- (164) 
 
R 
miR-10b HDAC4 
TMX 
Cell lines (165) 
miR-519a CDKN1A, PTEN, RB1 
Tumor tissues and 
cell lines 
(153) 
miR-221/222 
ESR1, CDKN1B, 
CTNNB1 
TMX and 
FULV 
(166-
168) 
miR-301 
FOXF2, PTEN, 
BBC3iso2, COL2A1 
TMX 
Tumor tissue, cell 
lines and xenografts 
(169) 
miR-155 SOCS6 (170) 
miR-210 
EFNA3, E2F3, 
RAD52, FGFRL1, 
MET 
Tumor tissue (147) 
 
AIs 
S 
Let-7f CYP19A1 LET Cell lines (171) 
miR-125b 
let-7c 
ERBB2 
LET and 
ANA 
Tumor tissues and 
cell lines 
(172) 
 
R miR-128a TGFBR1 LET Cell lines (173)  
Abbreviations: miR – microRNA; lncRNA – long non-coding RNA; S – sensitivity; R – resistance; ET – 
endocrine therapies; AntiE – anti estrogen; AIs – aromatase inhibitors; ANA – anastrozole; FULV – 
fulvestrant; DSCAM-AS1 - DSCAM Antisense RNA 1; BCAR4 - breast cancer anti-estrogen resistance 4; 
MTDH - Metadherin; CDK - cyclin-dependent kinase; ; ARPP19 - cAMP-regulated phosphoprotein 19; 
ESRRG - estrogen related receptor gamma; YWHAZ - Tyrosine 3-Monooxygenase/Tryptophan 5-
Monooxygenase Activation Protein Zeta; CCND1 - cyclin D1; ALCAM - Activated Leukocyte Cell Adhesion 
Molecule; ZEB - zinc finger E-box-binding homeobox; BCL-2 - B-cell lymphoma 2; BMP7 - bone 
morphogenetic protein 7;  GEMIN4 - gem (nuclear organelle)-associated protein 4; EZH2 - Enhancer of 
zeste homolog 2; EGFR - epidermal growth factor receptor; HDAC4 - Histone deacetylase 4; CDKN - 
Cyclin-Dependent Kinase Inhibitor ; PTEN - phosphatase and tensin homolog; RB1 – retinoblastoma 1; 
ESR1 - Estrogen Receptor 1; CTNNB1 - Catenin Beta 1; FOXF2 - forkhead box F2; BBC3iso-2 - BCL2 
Binding Component 3 isoform 2; COL2A1 - collagen type II alpha 1; SOCS - suppressor of cytokine 
signaling; EFNA3 - Ephrin A3; E2F3 - E2F transcription factor 3; RAD52 - RAD52 homolog, DNA repair 
protein; FGFRL1 - fibroblast growth factor receptor-like 1; MET - MET Proto-Oncogene, Receptor Tyrosine 
Kinase; CYP19A1 - cytochrome P450 family 19 subfamily A member 1; ERBB2 - erb-b2 receptor tyrosine 
kinase 2; TGFBR1 - transforming growth factor, beta-receptor 1; BCL2L11 - BCL2 like 11; ZNF217 - zinc 
finger protein 217. 
 
 
 
 
 
 
AIMS 
  
23 
 
The overall hypothesis of this Master Dissertation is that miRNAs that are deregulated in 
endocrine-resistant disease may be biologically and clinically relevant for luminal BrCa 
patients submitted to adjuvant ET. Thus, the main goal of this master dissertation is to 
identify miRNAs able to predict endocrine resistance among luminal BrCa patients 
undergoing ET, through the comparison of expression levels between BrCa cases that did 
or did not develop endocrine-resistance in long term follow-up. This might enable 
stratification of luminal BrCa cases into a low-risk subgroup, for whom additional adjuvant 
systemic treatment can be safely omitted, and patients who are at high-risk for recurrence 
potentially allowing the detection of resistance to ET at an early stage. Furthermore, we 
also intend to evaluate miRNA expression in normal breast and non-luminal tumor tissues 
to characterize the “baseline” status of miRNAs expression in healthy women and to 
evaluate miRNAs potential as diagnostic biomarkers.  
Thus, the specific aims of this work were: 
 Identifying a panel of deregulated miRNAs in endocrine-resistant tumors by a global 
expression assay in a discovery cohort composed of luminal A and B breast tumors 
from patients treated with adjuvant ET and with different outcomes;   
 Validate some of the identified miRNAs in a larger set of tissues samples, including 
luminal tumor tissues to evaluate their predictive and prognostic potential, as well as 
non-luminal tumor tissues and normal breast tissues to evaluate their diagnostic 
potential;  
 Evaluate the expression of the validated miRNAs in a cohort of primary tumor tissues 
and the paired metastasis in order to analyze their expression after the development of 
the resistance, rather than just before the therapy. 
 
 
 
 
 
 
 
MATERIAL AND 
METHODS 
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Patients and samples collection 
For this project, 176 BrCa samples were prospectively collected, after informed consent, 
from patients without metastasis at diagnosis aged between 40 and 75 years, which were 
submitted to surgery as first treatment from 1995 to 2002 at the Portuguese Oncology 
Institute of Porto (IPO Porto). Of these, 136 BrCa were luminal BrCa treated with adjuvant 
ET (with or without other adjuvant modalities). The remaining 40 BrCa samples were non-
luminal disease (12 HER2-enriched and 28 triple-negative breast tumors). Furthermore, 26 
normal breast tissue samples were collected from reduction mammoplasties of 
contralateral breast of BrCa patients. All specimens belonged to patients without BrCa 
hereditary syndrome and showed no evidence of preneoplastic/neoplastic lesions. After 
surgical resection, samples were immediately frozen at -80°C. Relevant clinical data was 
retrieved from patients’ charts. Additionally, 5 μm frozen sections were cut and stained 
with hematoxylin-eosin (H&E) staining for BrCa confirmation, ensuring that samples 
contained at least 70% of tumor cells, and that tissues obtained from reduction 
mammoplasties harbored normal epithelial cells. This study was approved by institutional 
ethical committee (CES 120/015). 
Luminal BrCa patients submitted to surgery as first treatment who did adjuvant ET (with or 
without other adjuvant modalities) and from whom both primary and metastatic tumors 
were available as FFPE tissue blocks were also included in this study. All primary tumors 
were invasive carcinomas and all samples had been formalin-fixed using the same 
standard procedure. Four μm sections were cut from each tissue block and stained with 
H&E, followed by a pathologist examination to select the most representative tumor lesion. 
The blocks containing the highest content of tumor tissues were then selected. All cases 
were revised by an experienced pathologist and graded according to Bloom and 
Richardson’s Modified system and staged according to the AJCC system (34). 
Breast cancer subtyping 
IHC was performed to identify the molecular subtype of each tumor tissue included in this 
study. Commercially available antibodies were used for ER (Clone 6F11, mouse, Leica), 
PR (Clone 16, mouse, Leica), HER2 (Clone 4B5, rabbit, Roche) and Ki-67 (Clone MIB-1, 
mouse, Dako). IHC was carried out in BenchMark ULTRA (Ventana, Roche) using 
ultraView Universal DAB Detection Kit (Ventana, Roche) according to manufacturer’s 
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instructions. Each case was evaluated by an experienced pathologist and was classified 
according to the College of American Pathologists recommendations (174). For HER2, 
cases with score 2+ were further assessed by fluorescence in situ hybridization. Each 
case was categorized according to ESMO guidelines (32). Cutoffs for Ki-67 and PR 
expression were 15% and 25% of positive cells, respectively. 
MicroRNA expression analysis 
RNA extraction from fresh frozen tissues 
Total RNA was extracted from fresh frozen tissues using the TRIzol® Reagent (Invitrogen, 
Carlsbad, CA, USA) according to manufacturer’s recommendations. Briefly, 12 μm 
sections from fresh frozen tissues were cut and placed in 2mL tubes. One mL of TRIzol® 
Reagent was added to the tissue-containing tubes followed by homogenization. Following 
an incubation of 5 minutes at room temperature, 200 μL of chloroform (Merck, Darmstadt, 
Germany) were added. This mixture was vortexed, incubated for 3 minutes at room 
temperature, and again centrifuged for 15 minutes at 10600 rpm and 4ºC. Then, the upper 
aqueous phase containing the RNA was transferred to a new eppendorf RNAse free and 
500 μL of isopropanol were added. The eppendorf was shaken vigorously and incubated 
for 10 minutes at room temperature for RNA precipitation. Another centrifugation for 10 
minutes at 10600 rpm and 4ºC was performed followed by supernatant discharge. The 
pellet was then washed twice with 1 mL of 75% ethanol. The washed pellet was then air 
dried and eluted in 30 μL of sterile distilled water (B. Braun, Melsungen, Germany). RNA 
purity ratios and concentrations were ascertained using a NanoDrop ND-1000 
spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) and RNA samples 
were stored at -80ºC.  
RNA extraction from formalin-fixed paraffin-embedded (FFPE) tissue 
samples 
RNA was extracted from 12 μm sections of FFPE primary tumors and the paired 
metastasis tissues, using a commercially available extraction kit (FFPE RNA/DNA 
Purification Plus Kit, Norgen Biotek, Thorold, Canada) in accordance with the 
manufacturer’s instructions. Briefly, the process starts with the deparaffinization of the 
FFPE samples, followed by the digestion with proteinase K [20mg/mL (NZYTECH, 
Portugal)] and the provided digestion buffer. Following an incubation of 15 minutes at 
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55ºC, the samples are centrifuged and the RNA-containing supernatant is separated from 
the DNA-containing pellet. Provided buffers and ethanol at 100% are then added to the 
RNA-containing solution that is then loaded into an RNA Purification Micro Column. The 
nucleic acids bind to the column and are then washed with provided wash solutions and, 
finally, eluted in 30 μL of elution solution. RNA purity ratios and concentrations were 
ascertained using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, 
Wilmington, DE, USA) and RNA samples were stored at -80ºC. 
MicroRNAs cDNA synthesis 
cDNA synthesis was performed using miRCURY LNA™ Universal RT miRNA PCR 
(Exiqon, Vedbaek, Denmark) following manufacturer’s instructions. Briefly, all RNA 
samples previously extracted were first adjusted to a 5ng/μL concentration, using sterile 
distilled water (B.Braun, Melsungen, Germany). On ice, per each RNase-free PCR tube, it 
was added: 2 μL of 5x Reaction Buffer, 5 μL of nuclease-free water (Exiqon), 1 μL of 
enzyme mix and 2 μL of previously concentration-adjusted RNA. Tubes were then 
vortexed gently and reverse transcription was performed in a Veriti® Thermal Cycler 
(Applied Biosystems, Foster City, CA, USA) according to the following conditions: 60 
minutes at 42ºC, followed by 5 minutes at 95ºC. Finally, samples were stored at -20ºC. 
This kit provides template for all miRNAs in only one reaction and has an amplification 
step to generate higher quantity of miRNAs (Figure 5). The use of Locked Nucleic Acid 
(LNA)-enhanced primers allows a much higher sensitivity and specificity to the assay. 
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Figure 5. A. A poly-A tail is added to the mature microRNA template. B. cDNA is synthetized using a Poly T 
primer with a 3’ degenerate anchor and a 5’ universal reverse primer sequence. C. The cDNA template is then 
amplified using microRNA-specific and LNA
TM
-enhanced forward and reverse primers. D. SYBR® Green is 
used for detection. Abbreviations: miRNA – microRNA; miR – microRNA; LNA - Locked Nucleic Acid. 
Amorim, Maria unpublished. 
Global expression assay 
Global miRNAs’ expression was evaluated using a Cancer Focus miRNA PCR Panel, 384 
well (V4.R) (Exiqon). Each plate, besides containing 80 lyophilized LNA™ miRNA primer 
sets focusing on cancer relevant human miRNAs, also contained interplate calibrators, 
candidate reference genes (miRNAs and snoRNAs) and one water blank. In each well, it 
was added 0.05 μL of cDNA previously synthesized, 5 μL of SYBR® Green master mix 
(Exiqon) and 4.95 μL of nuclease-free water (Exiqon). Quantitative reverse transcription 
polymerase chain reactions (RT-qPCR) were performed in the LightCycler 480 instrument 
(Roche Diagnostics, Manheim, Germany). Protocol consisted in incubation for 10 minutes 
at 95ºC, 45 cycles at 95ºC for 10 seconds and 60ºC for 1 minute. 
Before the analysis, inter-plate calibration (IPC) was performed. First, for each plate, the 
IPC replicates with standard deviation values higher than 0.5 were eliminated, and the 
average of the replicates for each plate was calculated, as well as the overall average 
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(average of IPC values from all plates). The calibration factor was calculated as the 
difference between plate average and overall average for each plate using the formula:  
Calibration factor = IPCplate – IPCoverall. 
Finally, each plate was calibrated by subtracting the calibration factor from all Ct values. 
The median values of miR-103a-3p, miR-207, miR-191-5p and SNORD38B were used for 
normalization, as these genes were the most stably expressed candidate reference genes 
(data not shown). Differences in expression values for target miRNAs were calculated 
using the 2-ΔCT method. The selection of deregulated miRNAs for further validation was 
made considering prominent fold change, good sensitivity for qRT-PCR detection (Ct 
values, in general, below 30), and novelty. 
Individual assays 
Initially, cDNA samples from fresh frozen tissues and from FFPE tissues were diluted 80x 
and 20x, respectively, in sterile distilled water (B. Braun, Melsungen, Germany). Then, on 
ice, per each well of a 384-well plate it was added: 5 μL of NZYSpeedy qPCR Green 
Master Mix (2x) (NZYTECH, Portugal), 1 μL of miRNA specific primer mix (miRNA LNA™ 
PCR primer set, Exiqon), and 4 μL of previously diluted cDNA. Each amplification reaction 
was performed in triplicate on a LightCycler 480 instrument (Roche Diagnostics, Manheim, 
Germany). Each plate also contained 2 negative template controls. RT-qPCR protocol 
consisted in a denaturation step at 95ºC for 2 minutes, followed by 40 amplification cycles 
at 95ºC for 5 seconds and 60ºC for 20 seconds. Melting curve analysis was performed 
according to instrument’s manufacturer recommendations. In Table 3 are present the 
target sequences of miRNAs analyzed in this study. 
SNORD38B was used as a reference gene for data normalization, as this gene was the 
most stably expressed over the whole range of the samples used for the global expression 
assay. Notwithstanding, the stability SNORD38B expression was empirically validated in 
more samples before the start of the individual assays. Relative miRNAs expression in 
each sample was calculated by the 2-ΔCT method, using the formula:  
Relative expression = 2-ΔCt, in which ΔCt = Cttarget miRNA – Ctreference miRNA 
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Table 3. Specific target sequence of miRNAs tested. 
Gene Target sequence 
SNORD38B (has) 
UCUCAGUGAUGAAAACUUUGUCCAGUUCUGCUACUGACAGUAAGUGAAGAUAAAGU
GUGUCUGAGGAGA 
hsa-miR-30b-5p UGUAAACAUCCUACACUCAGCU 
hsa-miR-30c-5p UGUAAACAUCCUACACUCUCAGC 
hsa-miR-181a-5p AACAUUCAACGCUGUCGGUGAGU 
hsa-miR-182-5p UUUGGCAAUGGUAGAACUCACACU 
hsa-miR-196a-5p UAGGUAGUUUCAUGUUGUUGGG 
hsa-miR-200b-3p UAAUACUGCCUGGUAAUGAUGA 
hsa-miR-205-5p UCCUUCAUUCCACCGGAGUCUG 
Methylation Analysis 
DNA extraction from fresh frozen tissues 
DNA extraction from fresh frozen tissues was performed using the phenol-chloroform 
method. Twelve-μm frozen sections were cut and placed in 15mL tubes. Then, 2.700 mL 
of SE buffer (75mM NaCl and 25 mM EDTA), 300 μL of 10% SDS and 25 μL of proteinase 
K [20mg/mL(NZYTECH, Portugal)] were added to the tissue-containing tubes. Samples 
were incubated at 55OC and additional proteinase K was added until complete digestion 
was achieved. Then, all samples were transferred to Phase Lock Light 15mL tubes (5 
Prime, Germany) and mixed with 3mL of phenol-chloroform with pH=8 (Sigma-Aldrich, 
USA).  After a centrifugation at 4000 rpm for 20 minutes, the aqueous phases were 
transferred to new 15mL tubes. For DNA precipitation, 6mL of cold absolute ethanol 
(Merkmilipore, Germany) and 1mL of ammonia acetate at 7.5M (Sigma-Aldrich, USA) were 
added to the samples following an overnight incubation at -20ºC. Samples were then 
centrifuged at 4000 rpm for 20 min and washed twice in 6mL ethanol 70%. The pellets 
were air dried and eluted in sterile distilled water (B.Braun, Melsungen, Germany). DNA 
concentration and purity were assessed using NanoDrop ND-1000 spectrophotometer 
(NanoDrop Technologies, Wilmington, DE, USA) and stored at -20ºC until further use. 
Sodium Bisulfite Modification  
Sodium bisulfite modification consists on the sulphonation, hydrolic deamination and alkali 
desulphonation of the unmethylated cytosines that are converted to uracil, while 
methylated cytosines are refractory to bisulphite-mediated deamination and remain 
unaltered (175). This protocol allows the differentiation of methylated from unmethylated 
cytosines upon PCR amplification, where uracil is amplified as thymine while methylated 
cytosines remain as cytosines. Genomic DNA from all samples and CpGenome™ 
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Universal Methylated DNA (Millipore, USA) were modified using EZ DNA Methylation-
Gold™ Kit (Zymo Research, USA) according to the manufacturer’s instructions. Briefly, the 
procedure comprised: bisulfite-mediated conversion of 1µg of DNA, using temperature 
denaturation in the Applied Biosystems Veriti 96-Well Thermal Cycler (Thermo Fisher 
Scientific, USA) to complement chemical denaturation; binding of the converted single-
stranded DNA to the membrane of a Zymo-Spin™ IC Column; washing of the membrane-
bound DNA; desulfonation of the membrane-bound DNA; washing to remove the 
desulfonation agent; elution of the pure converted DNA from the spin column in 60µL or  
20μL of sterile distilled water, depending on if it was genomic DNA or CpGenome™ 
Universal Methylated DNA, respectively. Finally, the modified DNA was stored at -80ºC 
until further use. 
Quantitative Methylation-Specific PCR 
Following sodium bisulfite modification, quantitative real-time methylation specific PCR 
(qMSP) was performed in order to analyze the methylation levels of our samples. qMSP is 
a quantitative method that combines methylation specific PCR (MSP) and real-time PCR 
principles, allowing a specific amplification of methylated target DNA and a reference 
sequence in separate reactions with higher sensitivity. In our study, Actin β (ACTβ) was 
used as a reference gene, allowing to normalize samples for DNA input and also to 
determine the quality of bisulfite conversion. Besides, the modified CpGenome™ Universal 
Methylated DNA was used as positive control and it was diluted in five serial dilutions by a 
5x dilution factor. These serial dilutions were run in each plate and used to generate a 
standard curve in order to allow the absolute quantification as well as ascertain PCR 
efficiency. 
Regions enriched for CpG dinucleotides (CpG islands) were predicted using the Methyl 
Primer Express Software v1.0 (Applied Biosystems, Foster City, CA, USA). The CpG 
island more distant from the MIR200B hairpin coding region was denominated promoter 1 
(P1), and the CpG island more proximal to the MIR200B hairpin was denominated 
promoter 2 (P2).  
Reactions were performed in 384-well plates using a LightCycler 480 instrument (Roche 
Diagnostics, Manheim, Germany).  Each plate contained all samples in triplicate, the five 
serial dilutions of the modified positive control in duplicated, and two negative controls. 
Briefly, per each well were added 1 μL of modified DNA and 5 μL of Xpert Fast SYBR 2X 
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Master Mix (GRiSP, Porto, Portugal). The primer volume used from a 10mM solution of 
forward and reverse primers was 0.4 µL for ACTβ and miR-200b P1, and 0.2 µL for miR-
200b P2. Sterile distilled water was added until 10 μL of reaction volume were achieved. 
Primer sequences are listed in Table 4. PCR program consisted of a period of 3 minutes 
at 95°C for enzyme activation followed by 40 cycles with 3 seconds at 95°C and 30 
seconds at 60/64ºC, depending on the primer pair. 
For each gene, relative methylation levels were calculated using the formula: 
Relative Methylation levels = (Mean quantity of target gene/Mean quantity of ACTβ) x 
1000 
Table 4. Primer sequences and qMSP conditions for each gene studied. 
Gene Sequence Amplicon 
Annealing 
Temperature (
O
C) 
MIR200B (P1) 
F: 5’-GAG CGG AGA TTG GTT AGC-3’ 
141 60 
R: 5’- TGC AAA ACG ACG AAA CAA TAA -3’ 
MIR200B (P2) 
F: 5’-TGG ACG TGG TTC GGA TAT AC-3’ 
121 64 
R: 5’- CGT AGT TTC GGC GAC GTA G -3’ 
Statistical Analysis 
Comparisons for continuous variables were performed using non-parametric Mann-
Whitney U tests. Differences between paired samples were analyzed using a Wilcoxon 
paired sample test. Fold changes for single miRNAs were calculated using the 2-ΔΔCT 
method (176). Spearman nonparametric correlation test was performed to assess the 
association between continuous variables. Chi-square test or Fisher's exact test were used 
as appropriate to compare proportions between two groups. 
Receiver Operating Characteristic (ROC) curves were constructed to evaluate miRNAs 
diagnostic performance and the formula provided in Table 5 allowed the calculation of 
specificity, sensitivity, positive predictive value (PPV), negative predictive value (NPV) and 
accuracy. The cut-off value established to categorize samples as positive or negative for 
each miRNA was the highest value obtained by the ROC curve analysis [sensitivity + (1-
specificity)]. Logistic regression models were also performed to evaluate the potential of 
using two miRNAs as a panel to increase their diagnostic performance. Cases positive for 
both miRNAs were considered positive in the panel.  
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Table 5. Formulas used for the calculation of the 
biomarkers performance parameters. 
 Tumor Normal 
Total A B 
> cut-off C D 
< cut-off E F 
 
Sensitivity (%) (C/A) x100 
Specificity (%) (F/B) x 100 
PPV (%) (C/(C+D)) x 100 
NPV (%) (F/(E+F)) x 100 
Accuracy (%) [(C+F)/(A+B)] x 100 
Abbreviations: PPV - positive predictive value; 
NPV - negative predictive value. 
Some clinicopathological features were grouped, including pT stage (T1&T2 and T3&T4), 
pN stage (N0&N1 and N2&N3) and grade [grade (G)1&G2 and G3] (34). Age was 
categorized into four groups (≤44; 45-64; 65-74; ≥75), and miRNA expression levels were 
categorized according to 25th or 75th percentile. For the survival analysis, Cox-regression 
univariable and multivariable models were computed to assess standard 
clinicopathological variables and miRNAs prognostic value. Hazard Ratios (HR) along with 
respective 95% Confidence Interval (95%CI) were reported. Multivariable Cox models only 
included the statistically significant variables. Kaplan-Meier with log rank test was used to 
construct and compare survival curves according to categorized miRNAs expression 
levels. Endocrine resistance-free survival (ERFS) was defined as the time between 
surgery and the recurrence dates. Recurrences occurring after 12 months of completing 
ET were not considered events for this analysis. Disease-free survival (DFS) was defined 
as the time between surgery date and recurrence date. Distant metastasis-free survival 
(DMFS) was defined as the time between surgery and the development of distant 
metastases.  
Statistical analysis was performed using SPSS software (SPSS Version 20.0, Chicago, IL) 
and two-tailed p-values were considered statistically significant when p<0.05. Graphs were 
built using GraphPad 6 Prism (GraphPad Software, USA).  
 
 
 
 
 
 
 
 
 
RESULTS 
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Characteristics of study populations  
The discovery cohort, used for global expression assay analysis, consisted of four 
luminal A and four luminal B tumors from patients who relapsed, and the same number 
of patients that did not relapse after adjuvant ET. Patients that relapsed during adjuvant 
ET or within the first 12 months of completing adjuvant ET were considered endocrine-
resistant (Table 6). 
Table 6. Clinical and pathological data of luminal tumors included in the discovery cohort. 
 
Molecular  
Subtype 
Age at  
diagnosis 
Grade Stage ChT RT Recidive Site 
Endocrine- 
resistant 
Patients who 
relapsed 
Luminal A 
82 G2 IIIA NO NO Liver YES 
41 G3 IIA YES YES Bone YES 
60 UNKN IA NO YES 
Contralateral  
breast 
NO 
43 G2 IIB YES YES Lymph nodes NO 
Luminal B 
65 G3 IIIC YES YES Lung YES 
63 G2 IIIA NO YES Bone YES 
67 G2 IIB NO NO Bone NO 
66 G3 IIIA NO NO Locoregional NO 
 
Patients who 
did not 
relapse 
Luminal A 
70 G3 IIB NO YES 
n.a. n.a. 
68 G2 IIB NO YES 
69 G2 IIIA NO NO 
69 G2 IA NO YES 
Luminal B 
65 G3 IIIC YES YES 
72 G3 IIIC NO YES 
70 G1 IIB NO YES 
73 G1 IIIC NO YES 
Abbreviations: ChT – chemotherapy; RT – radiotherapy; G – grade; UNKN – unknown; n.a. – not 
applicable.  
Overall, 176 fresh frozen tumors and 26 normal breast tissues were included in this 
study (Table 7). Age distribution significantly differed between patients and controls 
(p=0.003). 
Table 7. Clinical and pathological data of tumors and normal 
breast samples used in this study. 
Clinipathological 
features 
Tumor 
tissues 
Normal breast 
tissues 
Patients (n) 176 26 
Age median (range) 61 (41-75) 54 (40-70) 
Molecular Subtype 
Luminal A 
Luminal B 
HER2-enriched 
Basal (TNBC) 
 
56 (31.8) 
80 (45.5) 
12 (6.8) 
28 (15.9) 
n.a. 
Abbreviations: HER2 - human epidermal growth factor receptor 2; 
TNBC – triple-negative breast cancer; n.a. not applicable.  
The validation cohort was composed of 136 fresh frozen luminal BrCa tissues and 26 
normal breast tissues. From the 136 luminal BrCa, 40 derived from patients which 
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recurred and 96 from patients that did not. Among 40 patients with BrCa recurrence, 22 
were considered endocrine-resistant. Clinical and pathological characteristics of 
patients and controls included in this study are shown in Table 8. Endocrine-sensitive 
and endocrine-resistant groups did not differ significantly concerning age distribution 
(p=0.127). As expected, among endocrine-resistant BrCa cases, luminal B tumors were 
more common (p=0.004), and consequently, the same trend was depicted for HER2-
positivity (p=0.024) and high Ki-67 index (p<0.001). Moreover, this group also showed 
more moderate- and high-grade (G2 and G3) BrCa cases (p<0.001). For the remaining 
clinicopathological features or treatment modalities no significant differences were 
depicted.  
Table 8. Clinical and pathological data of luminal tumors and normal breast samples included in 
the validation cohort. 
Clinipathological features Endocrine-sensitive Endocrine-resistant NBr 
Patients (n) 114 22 26 
Age median (range) 
61.5 (43-73) 60 (41-75) 
54 (40-70) 
61.0 (41-75) 
Molecular subtype (%) 
Luminal A 
Luminal B 
 
53 (46.5) 
61 (53.5) 
 
3 (13.6) 
19 (86.4) 
n.a. 
Histological type (%) 
Invasive carcinoma of NST (IDC) 
Invasive lobular carcinoma 
Other special subtype carcinoma 
Mixed type carcinoma 
99 (86.8) 
6 (5.3) 
1 (0.9) 
8 (7.0) 
19 (86.4) 
2 (9.1) 
1 (4.5) 
0 (0.0) 
n.a. 
Grade (%) 
G1 
G2 
G3 
Not determined 
 
19 (16.7) 
57 (50.0) 
31 (27.2) 
7 (6.1) 
 
0 (0.0) 
9 (40.9) 
11 (50.0) 
2 (9.1) 
n.a. 
Progesterone receptor status (%) 
Positive 
Negative 
 
96 (84.2) 
18 (15.8) 
 
15 (68.2) 
7 (31.8) 
n.a. 
HER2 receptor status (%) 
Positive 
Negative 
 
10 (8.8) 
104 (91.2) 
 
6 (27.3) 
16 (27.3) 
n.a. 
Ki-67 index (%) 
<15% 
>15% 
UNKN 
 
89 (78.1) 
20 (17.5) 
5 (4.4) 
 
7 (31.8) 
11 (50.0) 
4 (18.2) 
n.a. 
Pathological T Stage (%) 
pT1 
pT2 
pT3 
pT4 
Not determined 
 
34 (29.8) 
56 (49.1) 
3 (2.6) 
5 (4.4) 
16 (14.0) 
 
5 (22.7) 
14 (63.6) 
0 (0.0) 
1 (4.5) 
2 (9.1) 
n.a. 
Pathological N Stage (%) 
pN0 
p N1 
p N2 
p N3 
Not determined 
 
42 (36.8) 
43 (37.7) 
9 (7.9) 
5 (4.4) 
15 (13.2) 
 
8 (36.4) 
8 (36.4) 
3 (13.6) 
1 (4.5) 
2 (9.1) 
n.a. 
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Stage (%) 
I 
II 
III 
Not determined 
 
17 (14.9) 
63 (55.3) 
18 (15.8) 
16 (14.0) 
 
3 (13.6) 
12 (54.5) 
5 (22.7) 
2 (9.1) 
n.a. 
Adjuvant RT 
Yes 
No 
Not determined 
 
85 (74.6) 
19 (16.7) 
10 (8.8) 
 
19 (86.4) 
3 (13.6) 
0 (0.0) 
n.a. 
Adjuvant ChT 
Yes 
No 
Not determined 
 
39 (34.2) 
59 (51.8) 
16 (14.0) 
 
12 (54.5) 
8 (36.4) 
2 (9.1) 
n.a. 
Abbreviations: NBr – normal breast tissues; HER2 - human epidermal growth factor receptor 
2; RT – radiotherapy; ChT – chemotherapy; G – grade; n.a.- not applicable. 
Considering paired primary tumors and available metastasis, miRNA expression 
analysis was performed in 38 tumor samples (16 primary breast tumors and 22 paired 
metastasis) from 16 luminal patients with paired samples from primary breast tumors 
and corresponding metastasis (distant, nodal and/or local). The time between 
diagnosis of primary tumor and metastasis varied from 1.51 to 20.43 years (median 
7.27 years). Clinical and pathological characteristics of patients included are shown in 
Table 9. 
Table 9. Clinical and pathological data of primary tumor tissues and paired metastasis tissues used in 
this study. 
Patient 
number 
Age at 
diagnosis 
Molecular subtype  
of primary tumor 
Localization of 
metastasis 
Time interval after  
primary tumor (years) 
1 39 Luminal B Lung 20.43 
2 60 Luminal A Axillary lymph node 16.07 
3 36 Luminal B Bone marrow 3.45 
4 35 Luminal B Liver 11.05 
5 74 Luminal B Pleural 11.75 
6 64 Luminal B Liver 3.54 
7 78 Luminal B Breast Skin 2.73 
8 61 Luminal B Bone 2.76 
9 43 Luminal A Axillary lymph node 11.68 
10 55 Luminal B Breast Skin 6.55 
11 51 Luminal A Lung 6.43 
12 
 
63 Luminal B Pleural 2.90 
 
13 
56 Luminal B 
Breast skin 3.48 
Axillary lymph node 4.59 
 
14 
66 Luminal A 
Mediastinum 8.53 
Esophagus 8.93 
15 51 Luminal B 
Contralateral breast 6.44 
Axillary lymph node 6.52 
Pleural 11.02 
Contralateral breast 
skin 
11.39 
16 60 Luminal B 
Bone marrow 1.51 
Skin 3.38 
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Global expression assay analysis 
In the global expression assay, one luminal A case with recurrence was excluded from 
the analysis, due to low RT-qPCR success rate (25% of the miRNAs did not amplify, 
and the remaining had Ct values higher than 30). Likewise, three (miR-202-3p, -206 
and -20b-5p) out of the 80 miRNAs were excluded due to low real-time PCR success 
rates. 
The result of this analysis revealed that, in general, miRNAs had average expression 
levels lower in the recurrence group compared to the recurrence-free group (data not 
shown). MiRNAs with fold variation values higher than 1 were selected, resulting in a 
panel comprising 56 miRNAs (Appendix VI).  
Gene-specific assays 
Assessment of miRNA expression in luminal tumor tissues and 
normal breast tissues 
From the global expression assay analysis, miR-30b-5p, miR-181a-5p, miR-182-5p, 
miR-196a-5p, miR-200b-3p and miR-205-5p were selected for further validation. All 
these miRNAs disclosed prominent fold change and good sensitivity for qRT-PCR 
detection. MiR-30b-5p was chosen because most studies focused on other members of 
the miR-30 family (miR-30f) and, to the best of our knowledge, the predictive potential 
of miR-30b-5p had not been assessed previously (177-180). Correspondingly, miR-
181a-5p and miR-196a-5p were also chosen because their predictive potential in BrCa 
had not been assessed previously. MiR-200b was selected to confirm the reported 
association with endocrine-resistance in in vitro studies (92, 93). Finally, miR-182-5p 
was also selected to better ascertain its role in endocrine resistance due to 
controversial results in global expression assay, since it was overexpressed in luminal 
B tumors from recurrent patients and downregulated in luminal A tumors from recurrent 
patients. Furthermore, miR-30c-5p was chosen as a positive control since higher 
expression levels of this miRNA had been formerly positively associated with benefit of 
ET, in multivariable analysis, in advanced ER-positive BrCa (181). 
To determine “baseline” miRNA expression, 26 normal breast tissues were also 
analyzed, and we found that miR-181a-5p (p=0.0007), miR-182-5p (p<0.0001), miR-
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196-5p (p<0.0001) and miR-200b-3p (p<0.0001) expression levels were significantly 
higher whereas miR-205-5p expression levels were significantly lower (p=0.00056) in 
luminal BrCa tissues. No differences were depicted for the remainder miRNAs (Table 
10). 
Table 10. MicroRNAs and the respective fold variation values 
between luminal tumors and normal breast tissues.  
miRNA p-value 
Fold change  
(2
-ΔΔCт
) 
miR-30b-5p 0.275 - 
miR-30c-5p 0.880 - 
miR-181a-5p 0.0007 1.96 
miR-182-5p < 0.0001 5.43 
miR-196-5p < 0.0001 4.73 
miR-200b-3p < 0.0001 7.77 
miR-205-5p 0.00056 0.42 
 
Assessment of miRNA expression in non-luminal tumor tissues and 
evaluation of miRNAs diagnostic performance 
To further evaluate the potential of miR-181a-5p, miR-182-5p, miR-196a-5p, miR-200b-
3p and miR-205-5p as diagnostic biomarkers, non-luminal tumor tissues (HER2-
enriched and basal-like subtypes) were also analyzed. MiR-181a-5p (p=0.0023), miR-
182-5p (p<0.0001), miR-196-5p (p=0.0011) and miR-200b-3p (p<0.0001) expression 
levels were significantly higher in BrCa when compared to normals, whereas miR-205-
5p (p<0.001) was significantly lower in tumors comparing with normal breast tissues 
(Table 11 and Figure 6, left panel).  
Table 11. MicroRNAs and the respective fold variation 
values between luminal tumors and normal breast tissues. 
miRNA p-value 
Fold change  
(2
-ΔΔCт
) 
miR-181a-5p 0.0023 1.70 
miR-182-5p < 0.0001 6.45 
miR-196-5p 0.0011 3.62 
miR-200b-3p < 0.0001 7.69 
miR-205-5p 0.0012 0.36 
 
ROC curves (Figure 6, right panel) were constructed and empirical cut-off values were 
determined for all miRNAs with diagnostic potential. 
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MiR-182-5p and miR-200b-3p showed the higher Area Under the Curve (AUC) 
(AUC=0.9696 and AUC=0.9502, respectively). The performance of each miRNA 
individually was calculated using the empirical cut-off obtained by the ROC curve 
(Table 12).  
 Table 12. Performance of miRNAs expression as biomarkers for breast cancer detection in tumor tissues. 
MiRNA Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%) 
miR-181a-5p 40.909 96.154 98.630 19.380 48.020 
miR-182-5p 93.182 92.308 98.795 66.667 93.069 
miR-196-5p 53,977 88,462 96,939 22,115 58,416 
miR-200b-3p 81.250 96.154 99.306 43.103 83.168 
miR-205-5p 76.136 65.385 93.706 28.814 74.752 
Abbreviations: PPV - positive predictive value; NPV - negative predictive value. 
MiR-182-5p and miR-200b-3p showed the best diagnostic performance. MiR-182-5p 
showed the highest sensitivity (93.18%), whereas the highest specificity was obtained 
for miR-200b-3p expression levels (96.15%). However, both had low NPVs. These two 
miRNAs were combined in panel displaying a diagnostic performance with an AUC of 
0.9696 (Figure 7), 94.89% sensitivity and 100% specificity. Moreover, a remarkable 
100% PPV and 74.29% NPV was also obtained, corresponding to an overall accuracy 
of 95.55% (Table 13). 
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Figure 6. Box-plots (left panel) and the respective Receiver Operating Characteristic (ROC) Curves (right 
panel) for 182-5p (A), (B), miR-196-5p (C), miR-200b-3p (D) and miR-205-5p (E). A *** denotes p-value 
<0.001 and a **** denotes p-value < 0.0001 by non-parametric Mann-Whitney U test. Y-axis denotes 2
-ΔCT 
values multiplied by 1000. 
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Figure 7. Receiver Operating Characteristic (ROC) Curve for miR-182-5p and miR-200b-3p combined. 
Table 13. Performance of miR-182-5p and miR-200b-3p expression levels combined as biomarkers for 
detection of breast cancer in tumor tissues. 
Panel Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%) 
miR-182-5p/miR-200b-3p 94.89 100.00 100.00 74.29 95.55 
Abbreviations: PPV - positive predictive value; NPV - negative predictive value. 
Validation of selected miRNAs in endocrine-resistant and –sensitive 
luminal tumor tissues 
MiR-30c-5p (p=0.0041), miR-30b-5p (p=0.0396) and miR-200b-3p (p=0.0293) were 
significantly downregulated in tumor tissues from endocrine-resistant BrCa compared 
with endocrine-sensitive tumors (Figure 8). No differences were depicted for the 
remainder miRNAs expression levels (Table 14). 
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Figure 8. Box-plots of miR-30b-5p (A), miR-30c-5p (B) and miR-200b-3p (C) expression levels in tumor 
tissues from endocrine-sensitive and –resistant patients. A * denotes p-value <0.05 and a ** denotes p-
value <0.01 by non-parametric Mann-Whitney U test. Y-axis denotes 2
-ΔCT 
values multiplied by 1000. 
Table 14. MicroRNAs and the respective fold 
variation values between in endocrine-resistant and 
endocrine-sensitive tumors.  
miRNA p-value Fold change (2
-ΔΔCт
) 
miR-30b-5p 0.0396 0.46 
miR-30c-5p 0.0041 0.43 
miR-181a-5p 0.170 - 
miR-182-5p 0.096 - 
miR-196-5p 0.995 - 
miR-200b-3p 0.0293 0.52  
miR-205-5p 0.0565 -  
Association between miRNAs expression and 
clinicopathological features 
HER2-negative tumors showed significantly higher miR-30b-5p expression levels 
(p=0.0447). Additionally, miR-30c-5p expression levels were significantly associated 
with PR and HER2 status (p=0.0314 and p=0.0462, respectively), being higher in PR-
positive tumors and in HER2-negative tumors. Moreover, high grade (G3) BrCa 
displayed significantly higher miR-196a-5p and lower miR-205-5p levels (p=0.0266 and 
p=0.0268, respectively) compared to G1/G2 BrCa (Figure 9).  
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Figure 9. Box-plots of miR-30c-5p (A) expression levels according to PR-status (left) and HER2-status 
(right), miR-30b-5p (B) expression according to HER2-status, and miR-196a-5p (C) and miR-205-5p (D) 
expression according to grade. A * denotes p-value <0.05 by non-parametric Mann-Whitney U test. Y-axis 
denotes 2
-ΔCT 
values multiplied by 1000. 
Survival Analysis 
All survival analysis were censured at 15 years of follow-up. The median follow-up time 
was 121 months (17.6-180 months). At 15 years of follow-up, 79 (58.1%) patients were 
alive. Of these, 76 patients (55.9%) had no evidence of cancer and 3 patients (2.2%) 
harboured cancer. Additionally, 57 patients (41.9%) had deceased, 31 of which due to 
BrCa (22.8%).   
In univariable analysis, the majority of the standard clinicopathological parameters 
significantly associated with ERFS. Specifically, HER2-positivity (HR = 3.46, p=0.010), 
high Ki-67 index (HR=5.82, p<0.001), high grade (G3) (HR=2.69, p=0.028) and luminal 
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B subtype (HR=5.11, p=0.009), which disclosed worse ERFS (Appendix VII). 
Furthermore, higher miR-30b-5p, miR-30c-5p, miR-182-5p and miR-200b-3p levels 
predicted better ERFS (Table 15, Figure 10).  
 
 
Figure 10. Endocrine Resistance-free survival curves of miR-30b-5p (A), miR-30c-
5p (B), miR-182-5p (C) and miR-200b (D). Abbreviations: P25 – percentile 25. 
Spearman’s correlation was used to assess the correlation between miRNAs 
expression in tumor tissues in order avoid collinearity/multicollinearity. MiRNAs with the 
strongest correlation were miR-30b-5p and miR-30c-5p (R=0.842, p<0.001), and miR-
200b-3p and miR-182-5p (R=0.837, p<0.001). Besides, miR-30b-5p and miR-30c-5p 
were also correlated with miR-182-5p (R=0.685, p<0.001 and R=0.638, p<0.001, 
respectively) and miR-200b-3p (R=0.732, p<0.001 and R=0.730, p<0.001, 
respectively).  
In multivariable analysis, all miRNAs previously identified in the univariable model 
remained independent predictors of improved ERFS adjusted to molecular subtype. 
MiRNAs were run in separate analysis to avoid collinearity (Table 15). 
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Table 15. Univariable and multivariable cox regression models assessing the association between 
microRNAs expression levels and clinical outcome. 
Model Outcome Variable HR (95% CI) p-value 
Univariable 
Analysis 
ERFS 
miR-30b-5p expression categorized 
≤P25 
>P25 
 
1 
0.362 (0.156-0.838) 
0.018 
miR-30c-5p expression categorized 
≤P25 
>P25 
 
1 
0.311 (0.135-0.717) 
0.006 
miR-182-5p expression categorized 
≤P25 
>P25 
 
1 
0.194 (0.081-0.464) 
< 0.001 
miR-200b-3p expression categorized 
≤P25 
>P25 
 
1 
0.217 (0.091-0.518) 
0.001 
DFS 
miR-30b-5p expression categorized 
≤P25 
>P25 
 
1 
0.412 (0.208-0.817) 
0.011 
miR-30c-5p expression categorized 
≤P25 
>P25 
 
1 
0.426 (0.223-0.815) 
0.010 
miR-182-5p expression categorized 
≤P25 
>P25 
 
1 
0.213 (0.101-0.452) 
< 0.001 
miR-200b-3p expression categorized 
≤P25 
>P25 
 
1 
0.226 (0.110-0.465) 
< 0.001 
DMFS 
miR-30b-5p expression categorized 
≤P25 
>P25 
 
1 
0.465 (0.224-0.964) 
0.040 
miR-30c-5p expression categorized 
≤P25 
>P25 
 
1 
0.467 (0.234-0.932) 
0.031 
miR-182-5p expression categorized 
≤P25 
>P25 
 
1 
0.284 (0.126-0.644) 
0.003 
miR-200b-3p expression categorized 
≤P25 
>P25 
 
1 
0.287 (0.131-0.628) 
0.002 
Multivariable 
Analysis 
ERFS 
miR-30b-5p expression categorized 
1
 
≤P25 
>P25 
 
1 
0.367 (1.497-17.112) 
0.019 
miR-30c-5p expression categorized 
1
 
≤P25 
>P25 
 
1 
0.353 (0.152-0.818) 
0.015 
miR-182-5p expression categorized 
1
 
≤P25 
>P25 
 
1 
0.181 (0.075-0.434) 
< 0.001 
miR-200b-3p expression categorized 
1
 
≤P25 
>P25 
 
1 
0.218 (0.091-0.522) 
0.001 
DFS 
miR-182-5p expression categorized 
2
 
≤P25 
>P25 
 
1 
0.194 (0.091-0.415) 
< 0.001 
miR-200b-3p expression categorized 
2
 
≤P25 
>P25 
 
1 
0.246 (0.119-0.511) 
< 0.001 
DMFS 
miR-182-5p expression categorized 
3
 
≤P25 
>P25 
 
1 
0.191 (0.081-0.454) 
< 0.001 
miR-200b-3p expression categorized 
2
 
≤P25 
>P25 
 
1 
0.314 (0.143-0.691) 
0.004 
1 
Cox regression model adjusted for molecular subtype. 
2 
Cox regression models adjusted for HER2 status.
 
3 
Cox regression models adjusted for grade and HER2 status. 
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Abbreviations: ERFS – endocrine resistance-free survival; DFS – disease-free survival; DMFS – distant 
metastasis-free survival; P25 – percentile 25; HR – Hazard ratio; CI – confidence interval.  
To disclose the potential of miRNAs expression level as predictors of ERFS for each 
molecular subtype, a stratified analysis by luminal subtype was performed (Table 16). 
All miRNAs retained statistical significance in luminal B, but not in luminal A lesions.  
Table 16. Cox regression models stratified according to the clinicopathological features with statistical 
significance in the multivariable analysis.  
Outcome 
Layering 
Variable 
Variable HR (95% CI) p-value 
ERFS 
Luminal A 
miR-30b-5p expression categorized 
≤P25 
>P25 
- 0.661 
Luminal B 
miR-30b-5p expression categorized 
≤P25 
>P25 
 
1 
0.344 (0.140-0.848) 
0.020 
Luminal A 
miR-30c-5p expression categorized 
≤P25 
>P25 
 
- 
0.555 
Luminal B 
miR-30c-5p expression categorized 
≤P25 
>P25 
 
1 
0.344 (0.140-0.847) 
0.020 
Luminal A 
miR-182-5p expression categorized 
≤P25 
>P25 
- 0.689 
Luminal B 
miR-182-5p expression categorized 
≤P25 
>P25 
 
1 
0.145 (0.058-0.364) 
< 0.001 
Luminal A 
miR-200b-3p expression categorized 
≤P25 
>P25 
- 0.699 
Luminal B 
miR-200b-3p expression categorized 
≤P25 
>P25 
 
1 
0.178 (0.071-0.445) 
< 0.001 
DFS 
HER2-negative 
miR-182-5p expression categorized 
≤P25 
>P25 
 
1 
0.179 (0.058-0.364) 
0.002 
HER2-positive 
miR-182-5p expression categorized 
≤P25 
>P25 
 
1 
0.197 (0.058-0.364) 
 
0.004 
HER2-negative 
miR-200b-3p expression categorized 
≤P25 
>P25 
 
1 
0.235 (0.073-0.750) 
 
0.014 
HER2-positive 
miR-200b-3p expression categorized 
≤P25 
>P25 
 
1 
0.311 (0.113-0.858) 
 
0.024 
DMFS 
Grade 1&2 
miR-182-5p expression categorized 
1
 
≤P25 
>P25 
 
1 
0.249 (0.076-0.819) 
 
0.022 
Grade 3 
miR-182-5p expression categorized 
1
 
≤P25 
>P25 
 
1 
0.168 (0.044-0.642) 
 
0.009 
HER2-negative 
miR-182-5p expression categorized 
2
 
≤P25 
>P25 
 
1 
0.235 (0.089-0.625) 
 
0.004 
HER2-positive 
miR-182-5p expression categorized
2
 
≤P25 
>P25 
- 
 
 
0.053 
HER2-negative 
miR-200b-3p expression categorized 
≤P25 
>P25 
- 0.066 
HER2-positive 
miR-200b-3p expression categorized 
≤P25 
 
1 
0.033 
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>P25 0.219 (0.054-0.884) 
1 
Cox regression model adjusted for HER2 status. 
2 
Cox regression models adjusted for grade. 
Abbreviations: ERFS - endocrine resistance-free survival; DFS - disease-free survival; DMFS - distant 
metastasis-free survival; HER2 – human epidermal growth factor 2 receptor; P25 – percentile 25; HR – 
Hazard ratio; CI – confidence interval. 
Regarding DFS, in univariable analysis, HER2-positivity (HR = 3.33, p=0.0002), high 
Ki-67 index (HR=2.48, p=0.010) and high grade (G3) (HR=2.21, p=0.016) associated 
with worse DFS (Appendix VII). Interestingly, higher miR-30b-5p, miR-30c-5p, miR-
182-5p and miR-200b-3p expression levels associated with improved DFS (Table 15, 
Figure 11).  
 
Figure 11. Disease-free survival curves (Kaplan–Meier with log rank test) of miR-
30b-5p (A), miR-30c-5p (B), miR-182-5p (C) and miR-200b (D). Abbreviations: 
P25 – percentile 25. 
In the multivariable model, only miR-200b-3p and miR-182-5p were independent 
prognostic predictors adjusted for HER2 status (Table 15). After stratifying the analysis 
according to HER2 status, both miRNAs retained statistical significance in both HER2-
positive and HER2-negative BrCa (Table 16).  
Finally, DMFS was also performed, disregarding locoregional recurrences. In line with 
the results for DFS, in a univariable analysis, HER2-positivity (HR = 3.39, p=0.001), 
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high Ki-67 index (HR=2.27, p=0.029) and high grade (G3) (HR=2.25, p=0.020) 
associated with worse DMFS (Appendix VII). Besides, higher miR-30b-5p, miR-30c-
5p, miR-182-5p and miR-200b-3p expression levels also associated with better DMFS 
(Table 15). In multivariable analysis, miR-182-5p retained statistical significance 
adjusted for HER2 status and grade, whereas miR-200b-3p retained statistical 
significance adjusted for HER2 status only (Table 15). After stratifying analysis 
according to HER2 status and grade, miR-182-5p retained statistical significance in 
both low/intermediate and high-grade cancers, as well as in HER2-negative tumors, 
whereas miR-200b-3p only retained statistical significance in HER2-positive BrCa 
(Table 16). 
MicroRNAs’ expression analysis in paired metastasis  
MiR-30b-5p, miR-30c-5p, miR-182-5p and miR-200b-3p expression levels were further 
analyzed in primary breast tumors and corresponding metastasis. Only miR-30b-5p 
and miR-200b-3p expression levels were significantly different between primary tumors 
and the corresponding metastasis (p=0.008 and p=0.0009, respectively) (Figure 12). 
Namely, miR-30b-5p and miR-200b expression levels were significantly higher in 
metastatic lesions versus primary tumors in 10 of 16 patients and in 11 of 16, 
respectively, both with a fold variation higher than 1. Conversely, the same was not 
found for miR-30c-5p and miR-182-5p expression levels (Figure 13).  
 
Figure 12. MiR-30b-5p (A) and miR-200b-3p (B) relative expression levels in primary tumors and the 
corresponding metastasis. A ** denotes p-value <0.01 by non-parametric Wilcoxon paired sample test. Y-
axis denotes 2
-ΔCT 
values multiplied by 1000. 
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Figure 13.  Comparison of miR-30b-5p (A), miR-30c-5p (B), miR-182-5p (C) and miR-200b-3p (D) in 
primary breast tumors versus corresponding metastasis. X-axis represents each patient. Y-axis represents 
-ΔΔCt values; positive values correspond to higher expression in the distant metastasis versus 
corresponding primary breast tumor.   
Methylation Analysis 
Since miR-200b-3p downregulation might be due to abnormal DNA methylation, both 
miR-200b-200a-429 cluster promoter methylation levels were assessed. Thus, 
methylation analysis was performed in normal breast tissues and in 95 luminal cases 
[of 136 BrCa luminal cases (18 endocrine-resistant and 77 endocrine-sensitive)] with 
available DNA.  
Globally, P1 methylation levels were significantly higher in luminal BrCa than in normal 
breast tissues (p=0.0032), whereas P2 methylation levels were significantly higher in 
latter (p<0.0001). Moreover, P1 methylation levels only correlated with miR-200b-3p 
expression in tumor tissues (R=-0.410, p < 0.001) and P2 methylation levels 
51 
 
significantly correlated with miR-200b-3p expression levels in all breast tissues (R=-
0.485, p<0.001) (Figure 14).  
 
Figure 14. Relative miR-200b-3p promoter 1 (A) and promoter 2 (B) methylation levels in 
normal breast tissues and tumors. A ** denotes p-value <0.01 and a **** denotes a p<0.0001 
by non-parametric Mann-Whitney U test. Y-axis denotes relative methylation values multiplied 
by 1000. 
Nonetheless, P1 methylation levels were significantly higher in HER2-negative tumors 
comparing with HER2-positive tumors (p=0.0358) (Figure 15).  
 
Figure 15. Box-plots of promotor 1 (P1) relative 
methylation levels in HER2-negative and HER2-positive 
tumors. A * denotes p-value <0.05. Y-axis denotes relative 
methylation values multiplied by 1000. 
No significant differences were found for methylation levels between endocrine-
resistant and –sensitive luminal tumor tissues.  
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BrCa remains the most common malignancy in women and a major cause of morbidity and 
mortality (1). De-escalation of both systemic and local adjuvant treatment, paralleling 
trends in surgery, is critical to provide patient-tailored treatment and avoid harmful side 
effects (32, 182). Indeed, identification of luminal BrCa patients with low-risk for recurrence 
after or while on ET, for which additional adjuvant systemic treatment can be safely 
omitted, is very important. Furthermore, the identification of high-risk luminal BrCa patients 
requiring more aggressive treatment regimens might help avoiding recurrence and 
subsequent metastatic disease, which currently affects approximately 40% of luminal BrCa 
patients after adjuvant ET (69, 183). Thus, identification of biomarkers providing predictive 
and prognostic information in this group of patients is urgently needed. Assessment of 
specific miRNAs expression deregulation, which has been associated with several 
mechanisms underlying endocrine resistance or sensitivity (184) might provide such kind 
of information. Nonetheless, most of those studies have been performed in cancer cell 
lines and display several limitations, including absence of epithelial-stromal and tumor-host 
interactions, that could modulate sensitivity in vivo. Tissue analysis from patients treated 
with ET may allow for broader insight into biologically and clinically relevant miRNAs that 
may serve as markers of response or resistance to ET. Thus, we focused on the 
identification of aberrantly expressed miRNAs in endocrine-resistant BrCa, exploring its 
predictive and prognostic value in luminal BrCa patients treated with adjuvant ET. 
The first step of this study consisted on the profiling of miRNAs expression patterns, 
looking for differences between endocrine-sensitive and endocrine-resistant luminal BrCa. 
Hence, miR-30c-5p, miR-30b-5p, miR-181a-5p, miR-182-5p, miR-196-5p and miR-200b-
3p were selected for validation in a larger set of tissue samples.  
In addition to luminal tumors, miRNAs expression was also analyzed in normal breast 
tissues, to determine their “baseline” expression, and in non-luminal tumors, in order to 
evaluate miRNAs diagnostic potential. Upregulation of miR-182-5p and miR-196-5p and 
downregulation of miR-205-5p in our cohort of BrCa tissues are consistent with previous 
publications (185-192), providing indirect validation of our methodological approach. 
Contrarily, downregulation of miR-200b-3p in tumors compared to normal tissues has been 
previously reported (193, 194). However, these studies have used as controls normal 
tissues adjacent to carcinomas, which may not truly represent normal breast tissues. 
Regarding miR-181a-5p, downregulated levels were reported in BrCa patients’ bodily 
fluids, however, its overexpression had  been also described in other studies for tumorous 
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breast tissues (195, 196). These inconsistencies in miRNA expression patterns between 
tumor tissues and bodily fluids might be explained by the currently unknown origin of 
circulating miRNAs. MiR-182-5p and miR-200b-3p were the miRNAs with the best 
diagnostic performance. Remarkably, we demonstrated that the combination of these two 
miRNAs in a panel accurately detected BrCa in tissue samples with 94.89% sensitivity and 
100% specificity, corresponding to an overall accuracy of 95.55%. As far as we know, our 
study is the first reporting the diagnostic performance of these miRNAs in BrCa, although 
significantly higher miR-182-5p serum levels were already reported in BrCa patients (186).  
Considering our main goal, our results have also successfully confirmed the biomarker 
potential of miR-30c-5p, which was downregulated in endocrine-resistant BrCa patients 
and independently predicted better ERFS in luminal B BrCa patients. Moreover, miR-30c-
5p expression correlated with PR-positivity and HER2-negativity, two of the most important 
predictive factors for ET sensitivity (42). Interestingly, miR-30b-5p and miR-200b-3p 
displayed the same trend and together with miR-182-5p, also independently predicted for 
improved ERFS in luminal B BrCa patients. The lack of significance in luminal A subtype 
might be due to the small number of cases and events in our series. Importantly, we were 
able to validate, for the first time in primary BrCa, the association between miR-200b-3p 
and endocrine-resistance, only previously reported in in vitro models (155). Although 
several members of miR-30f have been reported as markers of favorable prognosis in 
BrCa (177-180), we revealed that miR-30b-5p might also be predictive of ET response. 
Finally, concerning miR-182-5p, our results extend previous observations on the 
correlation with clinical benefit from therapy with tamoxifen in advanced-stage BrCa, but 
only in univariable analysis (146). 
There remains an important question concerning the degree to which the correlation 
between miRNAs expression is actually a consequence of response to therapies rather 
than inherently aggressiveness of the tumor. To further evaluate this question, miRNAs 
prognostic significance was also assessed. Remarkably, we have showed that miR-182-5p 
and miR-200b-3p are not only predictive, but also independent prognostic markers. 
Downregulation of these miRNAs associated with decreased DFS in both HER2-positive 
and HER2–negative BrCa and independently predict DMFS in HER2-negative and HER2-
positive cancers, respectively. Because BrCa display higher miR-182-5p and miR-200b-3p 
levels than normal breast, one may suggest that in early breast carcinogenesis, 
overexpression of these miRNAs contribute to the emergence of malignant phenotype by 
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increasing cell proliferation and survival, in line with previous reports from in vitro studies 
(197-199), whereas in a subset of more aggressive BrCa, expression levels decrease, due 
to yet unknown causes. 
The role of miR-200b-3p as a prognostic marker in BrCa is not a novelty (193, 194). 
Indeed, members of miR-200f are known to act as enforcers of epithelial phenotype 
through either Zinc finger E-box-binding homeobox (ZEB)-dependent or –independent 
pathways (200). Intriguingly, most in vitro studies consistently attributed an oncogenic role 
to miR-182-5p (201, 202). Moreover, higher miR-182-5p expression levels were 
associated with poor clinical outcome in BrCa patients (203), contrarily to our findings. It 
should be recalled, however, that miR-182 is a member of a miRNA family comprising 
three homologous, coordinately expressed, miRNAs (miR-183, miR-182 and miR-196) that 
are clustered in chromosome 7q32.2 and that members of this cluster have been linked to 
both pro- and anti-metastatic behavior in BrCa, suggesting that miR-183/96/182 cluster 
members may have divergent functions which are regulated in a context- and tissue-
dependent manner (204-206). Furthermore, the 7q32.2 locus has been considered a 
metastasis suppressor locus, enduring genetic copy number losses in BrCa progression 
(207). Thus, the association between miR-182-5p downregulation and worse prognosis 
probably results from a complex molecular scenario and additional studies are required to 
discriminate which members of the miR-183/96/182 cluster may contribute and to which 
extent to BrCa prognosis. 
MiR-30c-5p, miR-30b-5p, miR-182-5p and miR-200b-3p expression was then evaluated in 
FFPE metastatic tissues and the paired primary tumors. The stability of miRNAs in FFPE 
tissues holds enormous potential, especially in BrCa in which late relapses occur 
frequently. Indeed, it allows miRNA reliable analysis after resistance development and not 
only just before the therapy, allowing to accurately assess molecular markers across time. 
MiR-200b-3p and miR-30b-5p expression levels were significantly higher in metastatic 
tissues when compared to paired primary tumor tissues. As previously mentioned, miR-
200b-3p strongly inhibits the early steps of the metastatic process (208, 209). However, 
metastasis is the result of a multi-step cascade and tumor cells need to undergo 
widespread modifications to successfully colonize other organs. Indeed, once circulating 
tumor cells extravasate from the blood vessels, these cells need to recover their epithelial 
properties by undergoing mesenchymal-to-epithelial transition (MET) (210). Several 
studies have been shown that miR-200f members are essential in promoting metastatic 
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colonization, in striking contrast to what happens in the early metastatic steps (211-213). 
So, the dynamic ability to first undergo EMT and subsequently MET is an important feature 
of metastatic cells, and miR-200f members modulation might be important in this plastic 
process. Indeed, it is not the first time that miR-200b expression is reported to be higher in 
metastatic tissues when compared to primary tumor tissues (211, 214). Regarding miR-
30b-5p, its up-regulation in BrCa metastasis has never been reported to date. 
Nonetheless, other members of the miR-30f have been already linked to EMT in this 
cancer model (177, 179, 180). Thus, additional studies are needed regarding miR-30b-5p 
functional role in BrCa cells. The lack of significant differences between primary tumor 
tissues and the corresponding metastasis for other miRNAs might indicate that the 
modulation of these miRNAs is not essential for the metastatic process. Nevertheless, it is 
important to recall that miRNAs expression is highly context- and tissue-dependent, and 
so, ideally, miRNA expression in normal metastasis-host tissues should also be assessed. 
We could then be able to ascertain if the differential expression of miRNAs in the primary 
tumors versus metastatic tissues are a consequence of their modulation in the metastasis-
host tissue. Indeed, we have observed that some metastasis of the same patient from 
different locations have different expression patterns. 
The exploitation of the mechanisms by which miRNAs might be deregulated in BrCa may 
deepen our understanding on their potential role and functional implications. An analysis of 
the literature revealed that  the cluster in which miR-200b-3p is included - miR-200b-200a-
429 – has two promoter regions with CpG enrichments (215). Furthermore, in vitro studies, 
found that the treatment of an endocrine-resistant BrCa cell line with the demethylation 
agent 5-aza-2’-deoxycytidine increased miR-200b expression (155). Therefore, we sought 
to determine whether miR-200b-3p plastic expression in luminal BrCa is regulated by 
aberrant DNA methylation. Overall, our results suggest that miR-200b P1 promoter 
methylation might be malignant-specific, while miR-200b P2 might be tissue-specific. 
Besides, miR-200b overexpression in tumor tissues might be due to the loss of P2 
methylation levels in tumor tissues. However, no methylation differences were found for 
both promoters between endocrine-resistant and -sensitive tumors, suggesting that miR-
200b-3p downregulation in endocrine-resistant tumors might be dependent on additional 
mechanism, such as the recruitment of repressive histone marks. Indeed, recent in vitro 
studies have suggested that in cancer cells, the miR-200b cluster is more prone to be 
silenced primarily through polycomb group-mediated H3K27me3 gene silencing than by 
DNA methylation (216, 217). MiR-200b cluster P1 and P2 methylation levels have been 
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previously analyzed in breast clinical samples in another study, in which higher P2 
methylation levels were similarly associated with HER2 positivity (218). Nevertheless, we 
firstly showed that miR-200b promotors’ methylation levels are differentially methylated in 
normal breast and BrCa tissues. 
  
 
 
 
 
 
 
 
CONCLUSIONS AND 
FUTURE PERSPECTIVES 
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Despite the recent achievements in the last years concerning the role of miRNAs in 
endocrine resistance, the implementation of miRNAs for clinical use remains at an early 
stage. Indeed, we have verified that there are widespread inconsistencies across several 
studies regarding miRNAs expression and functional role that might be attributable to 
differences in the type of biological samples under investigation, differences in the 
methodologies used and differences in the genes used for data normalization. These 
discrepancies highlight the need to standardize experimental conditions, as well as the 
need to validate the findings in additional independent cohorts before its clinical utility may 
be established in daily clinical practice.  
In this master dissertation, we have showed that miRNAs might be suitable markers for 
BrCa management. Indeed, miR-182-5p and miR-200b-3p combined in a panel 
demonstrated high sensitivity, specificity and accuracy for BrCa diagnosis. Additionally, 
these miRNAs were also shown to be independent prognostic factors. Moreover, miR-30b-
5p, miR-30c-5p, miR-182-5p and miR-200b-3p independently predicted longer ERFS in 
luminal B BrCa patients. Overall, our results suggest that a panel of miRNAs might be 
tested in primary tumor tissues to assess the likelihood of recurrence and resistance to ET 
in newly diagnosed luminal BrCa. Nevertheless, these miRNAs need to be carefully 
validated, ideally in multicenter studies, to generate more conclusive results. Furthermore, 
in vitro studies, including gain and loss of function assays following in vitro treatment with 
ET, are also critical to functionally characterize the role of these miRNAs.  
Thus, in near future, we intend to increase the number of luminal A tumors to accurately 
evaluate the predictive potential of these miRNAs in this molecular subtype.  
Besides, we have verified that miR-30b-5p and miR-200b-3p modulation might be 
important during the metastatic cascade, e.g. for the ability to first undergo EMT in the 
early metastatic steps and subsequently MET for successful colonization. Consequently, 
we plan to increase our cohort of primary tumors and paired metastasis.  
Moreover, it would be very interesting to assess the expression of these miRNAs in liquid 
biopsies, evaluating their potential as non-invasive biomarkers. Indeed, miRNAs in 
circulation would enable the noninvasive monitoring of the disease during the course of the 
treatment, which might allow the detection of resistance to ET at an early stage, improving 
the care of luminal BrCa patients. 
60 
 
 
Finally, we have hypothesized that the dynamic regulation of miR-200b-3p might be 
dependent on other epigenetic mechanisms rather than DNA methylation, which will be 
further explored using in vitro models. 
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Appendix I. Magnitude of risk of BrCa risk and protective factors with different scientific evidence. Adapted 
from (219). 
Characteristic 
Menopausal 
Status 
*
  
Comparison 
Category 
Risk Category Estimate of Effect # 
Traditional Risk Factors for Breast Cancer 
Age at menarche 
Both 
Absence of the 
Factor 
Greatest 
Risk Category 
OR 1.3 
Age at first live birth OR 1.9 
Age at menopause OR 1.5 
Family history of 
breast cancer in first-
degree relatives 
OR 1.7 (mother) 
OR 5.0 (two first-degree 
relatives) 
Proliferative benign 
breast disease 
OR 2.0 
OR 5.0 (atypical 
hyperplasia) 
Lobular carcinoma in 
situ 
OR 10 
Birthplace/ethnicity OR 1.5–2.5 
Newer Epidemiologic Risk Factors for Breast Cancer 
Demographic Factors 
Age (yr) 
Both 
40–44 
50–54 IRR 2.09 
75–79 IRR 4.11 
Race 
African 
American 
White 
IRR 1.16 
Asian/Pacific 
Islander 
IRR 1.42 
Hispanic IRR 1.57 
Genetic Factors 
BRCA1 mutation 
Both No mutation Mutation 
Lifetime risk 50–73% by 
age 50 and 65–87% by 
age 70 
BRCA2 mutation 
Lifetime risk 59% by age 
50 and 82% by age 70 
Hormonal Factors 
Oral contraceptive 
use 
Both Never users 
Current users RR 1.24 (1.15–1.33) 
≥10 yr since last 
use 
RR 1.01 (0.96–1.05) 
Postmenopausal 
hormone therapy use 
Postmenopausal 
Nonusers with 
an intact uterus 
Estrogen and 
progestin users 
HR 1.24 (1.01–1.54) 
Nonusers with a 
hysterectomy 
Estrogen users 
HR 0.80 (0.62–1.04) 
 
Circulating estradiol 
Premenopausal Lowest quartile Highest quartile OR 1.00 (0.66–1.52) 
Postmenopausal Lowest quintile Highest quintile RR 2.00 (1.47–2.71) 
Circulating estrone 
Premenopausal Lowest quartile Highest quartile RR 2.00 (1.47–2.71) 
Postmenopausal Lowest quintile Highest quintile RR 2.19 (1.48–3.22) 
Testosterone 
Premenopausal <1.13 nmol/L ≥2.04 nmol/L OR 1.73 (1.16–2.57) 
Postmenopausal Lowest quintile Highest quintile RR 2.22 (1.59-3.10) 
Other Biologic Factors 
Mammographic 
breast density 
Both <5% density ≥75% density RR 4.64 (3.64–5.91) 
Bone mineral density Postmenopausal 
Lowest quartile 
at each of three 
skeletal sites 
Highest quartile 
at each of three 
skeletal sites 
RR 2.70 (1.4–5.3) 
Circulating IGF-1 
Premenopausal 
25
th
 percentile 75
th
 percentile 
OR 1.93 (1.38–2.69) 
Postmenopausal OR 0.95 (0.62–1.33) 
III 
 
Circulating IGFBP-3 
Premenopausal 
25
th
 percentile 75
th
 percentile 
OR 1.96 (1.28–2.99) 
Postmenopausal OR 0.97 (0.53–1.77) 
Behavioral Factors 
Body mass index Postmenopausal <21.0 kg/m
2
 ≥33.0 kg/m
2
 ≥33.0 kg/m
2
 
Height 
Premenopausal 
<1.60 cm ≥1.75 cm 
RR 1.42 (0.95–2.12) 
Postmenopausal RR 1.28 (0.94–1.76) 
Weight Postmenopausal <60.0 kg ≥80.0 kg RR 1.25 (1.02–1.52) 
Alcohol use Both Never drinkers >12 g/day RR 1.10 (1.06–1.14) 
Smoking Postmenopausal Never smokers Smoked > 40 yr RR 1.5 (1.2–1.9) 
Night work Both 
No nightshift 
work 
Any nightshift 
work 
OR 1.48 (1.36–1.61) 
Dietary Factors 
Total fat intake 
Both Lowest quartile Highest quartile 
OR 1.13 (1.03–1.25) 
Saturated fat intake OR 1.19 (1.06–1.35) 
Meat intake OR 1.17 (1.06–1.29) 
Environmental Factors 
Ionizing radiation Both 
0–0.09 Gy 
exposure to 
Nagasaki or 
Hiroshima 
atomic bomb 
≥0.50 Gy 
exposure to 
Nagasaki or 
Hiroshima 
atomic bomb 
RR = 9 at age 0–4 
RR = 2 at age 35–39 
Possible Protective Factors for Breast Cancer 
Biologic Factors 
Bone fracture Postmenopausal 
No fracture in 
past 5 yr 
History of 
fracture 
OR 0.80 (0.68–0.94) 
Behavioral Factors 
Body mass index 
Premenopausal 
<21.0 kg/m
2
 ≥33.0 kg/m
2
 RR 0.58 (0.34–1.00) 
Physical activity <9.1 hr/wk ≥20.8 hr/wk OR 0.74 (0.52–1.05) 
NSAID use Both Nonusers 
Current user of 
any NSAID 
OR 0.80 (0.73–0.87) 
Dietary Factors 
Calcium (dietary) Postmenopausal ≤500 mg/day >1250 mg/day RR 0.80 (0.67–0.95) 
Folate (total) Both 150–299 μg/day ≥600 μg/day RR 0.93 (0.83–1.03) 
Soy 
Premenopausal 
Low intake High intake 
OR 0.70 (0.58–0.85) 
Postmenopausal OR 0.77 (0.60–0.98) 
Vitamin D (total) Postmenopausal <400 IU ≥800 IU RR 0.89 (0.77–1.03) 
*
Menopausal status at the time of diagnosis. 
#
 95% confidence intervals are given in parentheses. Abbreviations: HR - 
hazard ratio; IGF-1 - insulin-like growth factor-1; IGFBP-3 - insulin-like growth factor-1 receptor binding protein-3; IRR - 
incidence rate ratio; OR - odds ratio; RR -relative risk; NSAID - nonsteroidal anti-inflammatory drug; yr – years.
IV 
 
Appendix II. Nottingham combined histologic grade. Adapted from (36). 
Criteria 
Score 
1 2 3 
Glandular/Tubular 
differentiation 
>75 % 10-75 % <10 % 
of tumor area forming glandular/ tubular structures 
Nuclear pleomorphism 
Nuclei small with little increase in 
size in comparison with normal 
breast epithelial cells, regular 
outlines, uniform nuclear chromatin, 
little variation in size 
Cells larger than normal with 
open vesicular nuclei, visible 
nucleoli, and moderate 
variability in both size and shape 
Vesicular nuclei, often with 
prominent nucleoli, exhibiting 
marked variation in size and 
shape, occasionally with very 
large and bizarre forms 
Mitotic Counting ≤7 HPF 8-14 HPF ≥15 HPF 
 
Total Score 
3-5 
Grade 1 (Well differentiated) 
6 or 7 
Grade 2 (Moderately 
differentiated 
8 or 9 
Grade 3 (Poorly differentiated) 
Abbreviations: HPF – High-power field 
Appendix III. Tumor-node-metastases (TNM) staging system for carcinoma of the breast. Adapted from (220). 
TNM staing system 
Primary tumor (T) 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis 
Carcinoma in situ 
DCIS Ductal carcinoma in situ 
LCIS Lobular carcinoma in situ 
Paget’s 
Paget’s disease (Paget disease) of the nipple NOT associated with invasive carcinoma and/or carcinoma in situ (DCIS 
and/or LCIS) in the underlying breast parenchyma. Carcinomas in the breast parenchyma associated with Paget’s 
disease are categorised based on the size and characteristics of the parenchymal disease, although the presence of 
Paget’s disease should still be noted. 
T1 
 
Tumour ≤20 mm in greatest dimension 
T1mi Tumour ≤1 mm in greatest dimension 
T1a Tumour >1 mm but ≤5 mm in greatest dimension 
T1b Tumour >5 mm but ≤10 mm in greatest dimension 
T1c Tumour >10 mm but ≤20 mm in greatest dimension 
T2 Tumour >20 mm but ≤50 mm in greatest dimension 
T3 Tumour >50 mm in greatest dimension 
T4 
Tumour of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules) 
T4a Extension to the chest wall, not including only pectoralis muscle adherence/invasion 
T4b 
Ulceration and/or ipsilateral satellite nodules and/or oedema (including peau d’orange) of the skin, which do not meet 
the criteria for inflammatory carcinoma 
T4c Both T4a and T4b 
V 
 
T4d Inflammatory carcinoma 
Regional lymph nodes (N) 
Clinical (cN) 
cNX Regional lymph nodes cannot be assessed (e.g. previously removed) 
cN0 No regional lymph node metastases 
cN1 Metastases to movable ipsilateral level I, II axillary lymph node(s) 
cN2 
Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal 
mammary nodes in the absence of clinically evident axillary lymph node metastases 
cN2a Metastases in ipsilateral level I, II axillary lymph nodes fixed to one another (matted) or to other structures 
cN2b 
Metastases only in clinically detectedk ipsilateral internal mammary nodes and in the absence of clinically evident level 
I, II axillary lymph node metastases 
cN3 
Metastases in ipsilateral infraclavicular (level III axillary) lymph node(s) with or without level I, II axillary lymph node involvement; or in 
clinically detectedk ipsilateral internal mammary lymph node(s) with clinically evident level I, II axillary lymph node metastases; or 
metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement 
cN3a Metastases in ipsilateral infraclavicular lymph node(s) 
cN3b Metastases in ipsilateral internal mammary lymph node(s) and axillary lymph node(s) 
cN3c Metastases in ipsilateral supraclavicular lymph node(s) 
Pathological (pN) 
pNX Regional lymph nodes cannot be assessed (e.g. previously removed or not removed for pathological study) 
pN0 
No regional lymph node metastasis identified histologically 
pN0(i−) No regional lymph node metastases histologically, negative immunohistochemistry (IHC) 
pN0(i+) 
Malignant cells in regional lymph node(s) not >0.2 mm [detected by haematoxylin and eosin (H&E) staining or IHC 
including isolated tumour cell clusters (ITCs)] 
pN0(mol−) No regional lymph node metastases histologically, negative molecular findings (RT-PCR) 
pN0(mol+) Positive molecular findings (RT-PCR), but no regional lymph node metastases detected by histology or IHC 
pN1 
Micrometastases; or metastases in one to three axillary lymph nodes; and/or in internal mammary nodes with metastases detected by 
SLNB but not clinically detected 
pN1mi Micrometastases (>0.2 mm and/or >200 cells, but none >2.0 mm) 
pN1a Metastases in one to three axillary lymph nodes, at least one metastasis >2.0 mm 
pN1b 
Metastases in internal mammary nodes with micrometastases or macrometastases detected by SLNB but not clinically 
detectedl 
pN1c 
Metastases in one to three axillary lymph nodes and in internal mammary lymph nodes with micrometastases or 
macrometastases detected by SLNB but not clinically detectedl 
pN2 
Metastases in four to nine axillary lymph nodes; or in clinically detectedk internal mammary lymph nodes in the absence of axillary 
lymph node metastases 
pN2a Metastases in four to nine axillary lymph nodes (at least one tumour deposit >2.0 mm) 
pN2b Metastases in clinically detectedk internal mammary lymph nodes in the absence of axillary lymph node metastases 
pN3 
Metastases in ≥10 axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or in clinically detected ipsilateral internal 
mammary lymph nodes in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph 
nodes and in internal mammary lymph nodes with micrometastases or macrometastases detected by SLNB but not clinically detected; 
or in ipsilateral supraclavicular lymph nodes 
VI 
 
pN3a 
Metastases in ≥10 axillary lymph nodes (at least one tumour deposit >2.0 mm); or metastases to the infraclavicular 
(level III axillary lymph) nodes 
pN3b 
Metastases in clinically detectedk ipsilateral internal mammary lymph nodes in the presence of one or more positive 
axillary lymph nodes; or in more than three axillary lymph nodes and in internal mammary lymph nodes with 
micrometastases or macrometastases detected by SLNB but not clinically detectedl 
pN3c Metastases in ipsilateral supraclavicular lymph nodes 
Distant metastasis (M) 
M0 
No clinical or radiographic evidence of distant metastases 
cM0(i+) 
No clinical or radiographic evidence of distant metastases, but deposits of molecularly or microscopically detected 
tumour cells in circulating blood, bone marrow or other non-regional nodal tissue that are not >0.2 mm in a patient 
without symptoms or signs of metastases 
M1 Distant detectable metastases as determined by classic clinical and radiographic means and/or histologically proven >0.2 mm 
VII 
 
Appendix IV. Stage grouping system for carcinoma of the breast. 
Adapted from (220). 
Anatomic stage/prognostic groups T N M 
Stage 0 Tis 0 
0 
 
Stage IA 1 0 
Stage IB 
0 1mi 
1 1mi 
Stage IIA 
0 1 
1 1 
2 0 
Stage IIB 
2 1 
3 0 
Stage IIIA 
0 2 
1 2 
2 2 
3 1 
3 2 
Stage IIIB 
4 0 
4 1 
4 2 
Stage IIIC Any T 3 
Stage IV Any T Any N M1 
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ABSTRACT 
Although important advances in the management of breast cancer (BC) have been 
recently accomplished, it still constitutes the leading cause of cancer death in women 
worldwide. BC is a heterogeneous and complex disease, making clinical prediction of 
outcome a very challenging task. In recent years, gene expression profiling emerged as a 
tool to assist in clinical decision, enabling the identification of genetic signatures that better 
predict prognosis and response to therapy. Nevertheless, translation to routine practice 
has been limited by economical and technical reasons and, thus, novel biomarkers, 
especially those requiring non-invasive or minimally invasive collection procedures, while 
retaining high sensitivity and specificity might represent a significant development in this 
field. An increasing amount of evidence demonstrates that non-coding RNAs (ncRNAs), 
particularly microRNAs (miRNAs) and long noncoding RNAs (lncRNAs), are aberrantly 
expressed in several cancers, including BC. miRNAs are of particular interest as new, 
easily accessible, cost-effective and non-invasive tools for precise management of BC 
patients because they circulate in bodily fluids (e.g., serum and plasma) in a very stable 
manner, enabling BC assessment and monitoring through liquid biopsies. This review 
focus on how ncRNAs have the potential to answer present clinical needs in the 
personalized management of patients with BC and comprehensively describes the state of 
the art on the role of ncRNAs in the diagnosis, prognosis and prediction of response to 
therapy in BC. 
Key words: Biomarkers, microRNA, Long nonconding RNA, Diagnostic, Prognostic 
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BACKGROUND 
Breast cancer (BC) is one of the most common cancers with more than 1,300,000 cases 
diagnosed and 450,000 deaths occurring each year, worldwide 1. Due to earlier diagnosis 
and implementation of adjuvant chemo- and hormone-therapies (HT), BC mortality has 
been declining, although it remains the most common cause of cancer-related death 
among women 2. At present, most patients are diagnosed at localized disease stage, but 
20-85% of all patients will eventually develop recurrent and/or metastatic disease 3.  
BC is intrinsically heterogeneous, representing a spectrum of diseases with distinct 
morphology, molecular traits, prognosis, and therapeutic options. On the basis of gene 
expression, BC cases are often classified into one of five intrinsic subtypes 4. The large 
majority of estrogen receptor (ER) and/or progesterone receptor (PR)-positive (+) tumors 
are of the luminal subtypes that typically express luminal cytokeratins (CK) 8 and 18 5. 
These tumors are further subdivided into Luminal A and Luminal B, according to the 
expression levels of Ki67, a nuclear protein that is associated with cellular proliferation. 
The ER and PR-negative (-) tumors are divided into three subtypes:  the basal-like 
subtype, characterized by the expression of CK 5/6 and CK17; the human epidermal 
growth factor receptor 2 (HER2)-enriched subtype, which are positive for HER2; and the 
“normal-like” subtype, characterized by a similar gene expression pattern as the normal 
breast. This last subtype remains enigmatic as to whether it represents a separate subtype 
or a technical artifact introduced by the contamination of cancerous cells with their 
surrounding normal tissue 5.  
BC clinical decisions are based on routine assays for ER, PR and HER2, as well as Ki67 6. 
The molecular phenotype of the tumor is indicative of the most suitable treatment, i.e., 
either endocrine therapy (ET) in hormone receptor positive or HER-targeted therapy in 
HER2+ tumors 7. Globally, ER- tumors have a poorer prognosis in the first few years after 
diagnosis, but after 5 to 10 years, ER+ tumors demonstrate the poorest outcome 8. 
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However, not all ER+ BCs behave similarly, and the studies conducted in recent years 
show that luminal A and B BCs should be perceived as distinct entities 9. Luminal A 
subtype has been shown to exhibit good clinical outcomes with ET whereas the pattern of 
mortality rates associated with the luminal B tumors is similar to those of the non-luminal 
subtypes 10. However, Luminal A, the most frequently occurring BC subtype, is also the 
most heterogeneous subtype, both molecularly and clinically 11. Indeed, ER expression 
itself fails to predict which ER+ tumors will respond or be resistant to different modalities of 
ET, and resistance has been reported in 30% of ER+ BCs 12.  
Due to molecular heterogeneity, clinical decisions based solely upon histopathologic 
analysis or one or small numbers of genes or their coding proteins in the tumor tissue are 
limited. Moreover, the widespread use of gene-expression profiling using commercially 
available molecular signatures for the examination of multiple expressed genes is also of 
limited application, primarily due to the cost and to reproducibility issues 13,14.  
Recently, several studies have reported on the association between microRNAs (miRNAs) 
and BC, suggesting its usefulness as disease biomarkers. Interestingly, miRNA detection 
in bodily fluids appear to have superior accuracy than messenger RNA (mRNA) profiling 
because of their high tissue-specificity, stability, and aberrant expression in different tumor 
types 15. MiRNAs have the additional advantage of being long-lived in vivo 16 and very 
stable in vitro 17,18, which might be critical in a clinical setting. Indeed, tumor cells were 
suggested to release miRNAs stabilized by their association with RNA-binding proteins 
and by their incorporation into microvesicles 19,20.The emergence of non-coding RNA 
(ncRNAs) as biomarkers may add robustness to the current molecular classification of 
human BC, with the potential for improving diagnosis and monitoring of BC. Thus, in this 
review, we will focus on ncRNAs as potential diagnostic, predictive and prognostic 
biomarkers for BC management. 
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Evidence Acquisition  
For the selection of bibliography, PubMed publications on BC were searched using the 
keywords breast cancer, noncoding RNAs and microRNAs. References of all articles were 
also examined for additional potentially relevant studies. The criteria for article selection 
were: written in English, central theme based on ncRNAs and BC. Original reports were 
selected based on the detail of analysis, mechanistic support of data, novelty, and 
potential clinical usefulness of the findings.  
 
NON-CODING RNAS 
It is currently acknowledged that at least 98% of the mammalian genomes and other 
complex organisms are transcribed into ncRNAs 21. In fact, ncRNAs that were previously 
thought to be “transcription noise”, are believed to be a hidden layer of internal signals that 
control various levels of gene expression, playing a significant role in cell homeostasis and 
its deregulation is involved in the development of several human diseases. The family of 
ncRNAs, in addition to the well know transfer RNAs (tRNAs), ribosomal RNAs (rRNAs), 
and small nucleolar RNAs (snoRNAs), includes the recently discovered long noncoding 
RNAs (lncRNAs) and miRNAs. 
Transfer RNA (tRNA) 
tRNAs are small ncRNA transcripts, typically with 76 to 90 nucleotides (nt) in length, that 
serve as physical link between mRNA and the aminoacid sequence of proteins 22. In 2009, 
Pavon-Eternod 23 analyzed genome-wide tRNA expression and found that tRNAs were 
increased in BC compared to normal breast tissues. Their results also suggested a 
functional consequence of tRNA over-expression in tumor cells, which seems to be 
selective and may increase the translational efficiency of genes relevant to cancer 
development and progression. 
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Recent studies indicated that precise cleavage of tRNAs generate active products 24. 
Indeed, high levels of tRNA-derived miRNas or of tRNA-derived molecules termed 5’tRNA 
halves are likely to be a manifestation of tRNA over-expression. Park 25 reported that miR-
1280 - a tRNA-derived fragment - was significantly up-regulated in blood of BC patients, 
particularly in metastatic BC patients, compared to healthy subjects and decreased 
significantly after systemic treatment in patients who responded to treatment, while 
increasing in the blood of patients with non-responding tumors. Moreover, BC is 
associated with expression deregulation– either increase or decrease – in the circulating 
levels of 5’tRNA halves derived from specific tRNA isoacceptors 26, and changes in 
circulating 5’tRNA halves were associated with specific tumor features, such as 
ER/PR/HER2-status, raising the possibility of a causal connection with some aspects of 
breast carcinogenesis. 
Long noncoding RNAs (lncRNAs)  
LncRNAs are ncRNA molecules usually longer than 200 nts that do not fit into known 
classes of small or structural RNAs, and that may function as either primary or spliced 
transcripts 27. LncRNAs may be transcribed from various genomic locations, as well as in 
their own stand-alone position in the genome  - long intergenic non-coding RNAs 
(lincRNAs) 28. LncRNAs have gained widespread attention in recent years as a potentially 
new and crucial layer of biological regulation, controlling cell cycle, apoptosis and 
differentiation by acting as protein-DNA or protein-protein scaffolds, miRNA sponges, 
protein decoys, and regulators of translation 29.  
LncRNAs in breast cancer 
LncRNAs were already found to be differentially expressed in BC tissues compared to 
normal breast tissues and recent studies have demonstrated their key regulatory role in 
gene expression and BC biology through diverse mechanisms 30. 
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Diagnostic biomarkers 
Expression levels of lncRNAs have been investigated in BC tissues compared to normal 
tissues indicating that some may be potential biomarkers for BC diagnosis. Ding et al 
found that lincRNA-BC2 and lincRNA-BC5 were consistently up-regulated (more than 2-
fold) in BC samples, whereas lincRNA-BC4 and lincRNA-BC8 were down-regulated 31. 
Moreover, lincRNA-BC4 expression was significantly lower in grade III BC, and lincRNA-
BC5 expression was significantly higher in grade III, whereas lincRNA-BC2’ expression 
significantly associated with lymph node metastasis (LNM). Remarkably, lncRNAs’ 
expression was also found to be highly associated with BC subtype classification 32. Later 
studies have also demonstrated that lncRNAs are amenable for detection in bodily fluids. 
For example, the serum expression levels of circulating lncRNA RP11-445H22.4 were 
found significantly increased in BC patients, identifying BC cases with 92% sensitivity and 
74% specificity 33. 
Prognostic biomarkers 
In addition to lncRNAs potential use as diagnostic biomarkers, they have been suggested 
as valuable prognostic biomarkers. Zhao and co-workers identified a set of lncRNAs that 
distinguished low-risk from high-risk BC patients 34. Patients with significantly higher 
LINC00324 expression and lower PTPRG antisense RNA 1 (PTPRG-AS1) and small 
nucleolar RNA host gene 17 (SNHG17) expression showed longer overall survival (OS). In 
another study, high SPRY4 intronic transcript 1 (SPRY4-IT1) expression levels were also 
associated with poorer prognosis, specifically shorter disease-free survival (DFS) 35.  
HOX transcript antisense RNA (HOTAIR) overexpression in BC tissues has been 
associated with higher invasion and metastatic capacities, and suggested as an OS and 
progression free-survival (PFS) biomarker 36. Specifically, in ER+ BC patients, HOTAIR 
expression was shown to independently predict the risk of metastasis 37. Similarly, 
metastasis-associated lung adenocarcinoma transcript 1’s (MALAT1) upregulation was 
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found in primary BC and its levels were further increased in the respective metastases 38. 
Conversely, BC040587 39, neuroblastoma associated transcript 1 (NBAT1) 40 and 
eosinophil granule ontogeny transcript (EGOT) 41 were found downregulated in BC 
samples and associated with poor prognosis. Furthermore, LINC00472 high expression 
levels in BC tissues associated with less aggressive behavior and more favorable outcome 
42.  
Predictive biomarkers 
LncRNAs have been suggested as valuable predictive biomarkers. Indeed, BC anti-
estrogen resistance 4 (BCAR4) overexpression has been shown to predict tamoxifen 
resistance 43. On the other hand, lincRNAs LINC00160 and LINC01016 were both found 
highly overexpressed in ER+ tumors compared to ER- tumors and normal tissues, being 
significantly associated with longer OS of luminal A BC 44. Interestingly, these lincRNAs 
may identify patients that respond to ET, functioning as robust predictive biomarkers for 
ER activity.  
Besides ET resistance, progression or recurrence due to resistance to trastuzumab or 
other commonly used therapeutic approaches, such as chemotherapy and radiotherapy, 
also constitute a significant clinical challenge. LncRNA activated by TGF-β (ATB) has been 
associated with trastuzumab resistance in BC patients 45. Conversely, lncRNA colon 
cancer associated transcript 2 (CCAT2) overexpression identified a subset of BC patients 
that might not benefit from Cyclophosphamide, Methotrexate and Fluorouracil (CMF) 
based adjuvant chemotherapy 46. Finally, Chen et al. 47 demonstrated that overexpression 
of lincRNA Regulator of Reprogramming (ROR) is associated chemotherapy tolerance.  
MicroRNAs (miRNAs) 
MiRNAs are endogenous, small non-coding single-stranded RNAs with an approximate 
length of 22 nt, encoded by various genomic regions in either sense or antisense 
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orientation 48. MiRNAs are critical for a wide range of biological processes exerting a finely 
tuned regulation of gene expression at posttranscriptional level 49.  
MiRNAs in breast cancer 
MiRNA dysregulation in cancer was first reported in 2002 50. Since then, the emergence of 
miRNAs has been one of the defining developments in cancer biology with several studies 
demonstrating a differential miRNA expression profile and global miRNA downregulation in 
human malignancies compared with paired normal tissues. Indeed, aberrant miRNA 
expression in human tumors is not just a casual association, as it exerts a causal role at 
different steps of the tumorigenic process. Some of the miRNAs that will be mentioned 
here have already been associated with several hallmarks of cancer 3,51,52 (Figure 1). 
 
Figure 1. MiRNAs as key regulators of BC hallmarks. Expression of miRNAs (↑up-regulated and ↓ down-
regulated) grouped according to their function in the hallmarks of breast cancer: circulating miRNAs (red) and 
non-circulating miRNAs with prognostic (bold) and predictive (underlined) value. Abbreviations: miR – 
microRNA; fam – family. 
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MiRNAs might be classified into oncogenic miRNAs (oncomiRs) or tumor suppressor 
miRNAs, depending on their targets. OncomiRs act by repressing the expression of tumor 
suppressor genes and are frequently upregulated in cancer. Tumor suppressor miRNAs 
act by targeting oncogenes and are frequently downregulated in cancer. However, this 
miRNA categorization may be inaccurate, as many studies have shown that miRNAs may 
present a dual function, with oncogenic or tumor suppressive properties based on tumor 
type and cellular context 53. Furthermore, some miRNAs are consistently up- or down-
regulated in tumor specimens, whereas other, such as miR-221 and miR-10b, exhibit a 
more irregular pattern  of expression 54. MiR-10b was found downregulated in all BCs from 
metastasis-free patients, but elevated miR-10b levels were found in primary tumors from 
patients harboring metastasis, suggesting that miR-10b might be differentially deregulated 
along tumor progression 55. Volinia et al. 56 studied this change in miRNA expression along 
cancer progression and found that let-7d, miR-210 and miR-221 were downregulated in 
the ductal carcinoma in situ compared to normal breast tissue, but it was found to be 
upregulated in the transition to invasive carcinoma, featuring an expression reversal along 
the cancer progression path. 
Diagnostic biomarkers 
Each tumor type has a distinct miRNA signature that distinguishes it from normal tissues 
and other cancer types 15. In 2005, Iorio et al. 57 identified a 13-miRNA signature that could 
discriminate BC from normal breast tissues with perfect accuracy. Among the differentially 
expressed miRNAs, the most consistently dysregulated were miR-125b and miR-145 
(downregulated), and miR-21 (up-regulated). Since then, many studies have looked at 
specific miRNAs dysregulated in BC with a diagnostic purpose. 
In addition to studies of miRNA expression patterns in tissues, expression profiling studies 
of miRNAs in bodily fluids have been performed, to investigate whether bodily fluids could 
be used to differentiate BC patients from healthy individuals. In this context, Heneghan et 
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al. 58 found significantly higher levels of miR-195 and let-7a in the blood of BC patients 
compared to healthy controls, detecting BC with high sensitivity and specificity. Several 
studies have also highlighted differences in the profiles of serum and plasma miRNAs in 
cancer compared to healthy individuals. MiR-222, for example, was significantly increased 
in the serum of BC patients 59, while higher miR-205 levels have been found in the sera of 
healthy individuals compared to BC patients 60. Furthermore, Zhao et al. found that miR-
195 was downregulated in the plasma of BC patients compared to healthy subjects 61. 
MiRNA profiles show better diagnostic performance as well as increased sensitivity than 
individual miRNAs, for BC detection. Hu et al. identified a 4-miRNA signature with 
increased concentrations in the serum of BC patients that could distinguish BC patients 
from healthy individuals with 92.1% and 93.4% sensitivity and specificity, respectively 62. 
More recently, Zhang and co-workers  have found a 3-miRNA signature in serum as a 
diagnostic biomarker for non-invasive early detection of BC 63, whereas Ng et al. reported 
that the combination of miR-145 and miR-451 levels in plasma may discriminate normal 
individuals from BC patients, both at early and advanced stages of disease 64. Finally, Cuk 
et al. have also found a panel of deregulated plasma miRNAs that were elevated in 
women with benign and stage I or II BC, that might be attractive candidates for early BC 
detection 65.  
Table 1 summarizes these and others non-circulating and circulating miRNAs already 
described and validated in large cohorts for BC diagnosis. 
 
 
 
 
 
12 
 
Table 1. Non-circulating and circulating miRNAs for BC diagnosis. 
 miRNAs Sample 
Validation 
techniques 
Samples size Sensitivity Specificity AUC Refs. 
N
o
n
-c
ir
c
u
la
ti
n
g
 m
iR
N
A
s
 
↑ miR-23a 
BC 
tissues 
qRT-PCR 
76BC vs. 36 
benign vs. 36N 
0.829 0.100 0.915 
66
 
↑ miR-155,  
-21, -184, 
 -518b, -572,  
-601, -622 
↓ miR-125b 
TaqMan 
qRT-PCR 
24BC vs. 6N . . . 
67
 
↑miR-660-5p 
↓miR-99b-5p, 
-574-3p,  
-769-5p 
SYBR Green 
qRT-PCR 
56BC vs. 9N 
60BC vs. 11N 
- - - 
68
 
 
C
ir
c
u
la
ti
n
g
 m
iR
N
A
s
 
↑miR-222 
Serum 
qRT-PCR 50BC vs. 50N 0.74 0.60 0.671 
59
 
↑miR-16, 
-25, -222, 
-324-3p 
TaqMan 
qRT-PCR 
76BC vs. 76N 0.921 0.934 0.928 
62
 
↑miR-145, 
-155, -382 
qRT-PCR 61BC vs. 10N 0.976 0.100 0.988 
69
 
↓miR-205 qRT-PCR 58BC vs. 93N 0.862 0.828 0.84 
60
 
↑miR-199a,  
-29c, -424 
SdM-RT-
PCR 
76BC vs. 52N 0.776 0.846 0.901 
63
 
↑ miR-92a, 
miR-133a 
qRT-PCR 
132BC vs. 
101N 
- - 0.91 
70
 
↓miR-200c 
Whole 
blood 
qRT-PCR 57BC vs. 20N 0.90 0.702 0.79 
71
 
↓miR-145 
↑miR-451 
Plasma 
TaqMan 
qRT-PCR 
70BC vs.50N 0.900 0.920 0.931 
64
 
↑miR-127-3p,  
-148b, -376a, 
-376c, -409-
3p, -652, -801 
TaqMan 
qRT-PCR 
120BC vs. 60N 0.800 0.720 0.81 
65
 
↓miR-195 
SYBR Green 
qRT-PCR 
210BC vs. 
102N 
0.69 0.892 0.859 
61
 
↑miR-16, -
148a, -19b,  
-22a 
↓Let-7d,   let-
7i, miR-103,  
-107 
qRT-PCR 108BC vs. 88N 0.91 0.49 0.81 
72
 
↑miR-505–5p 
↑miR- 96–5p 
qRT-PCR 
114BC vs. 
116N 
- - 
0.72 
0.72 
73
 
↑
Up-regulated 
↓ 
Down-regulated 
Abbrevations: N – normal; SdM- Serum-direct Multiplex. 
Despite the identification of non-circulating and circulating miRNAs aberrantly expressed in 
BC, discrepancies remain among the different miRNA signatures reported, probably due to 
differences in clinicopathological variables and the intrinsic heterogeneity of BC. 
Therefore, an attempt has been made to develop miRNA signatures that might reflect 
distinct histopathological features of BC.  
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Indeed, altered miRNAs levels that predict ER, PR and HER2 receptor status have already 
been identified (Table 2). Lowery et al. identified a 15-miRNA predictive signature 
corresponding to the expression of ER, PR, and HER2 receptor status 74. Recently, 
Cizeron-Clairac and co-workers  found that 20 miRNAs were significantly deregulated in 
ER+ compared to ER- BCs 75. Up-regulation of miR-1244 and downregulation of miR-30e 
were specific of ER- tumors, whereas downregulation of miR-18a, miR-18b and miR-654-
3p and up-regulation of miR-342-5p and miR-190b were specific of ER+ tumors.  
Table 2. MiRNAs which increased expression predicts for ER, PR and HER2 receptor status in BC.  
ER status Refs. 
ER
+
 miR-342, -217, -190b, -218, -342-5p 
74-76
 
ER
-
 miR-299-3p, -190, -135b, -182, -21, -30e, -1244 , -10b, -375 
58,74,75,77,78
 
PR status  
PR
+
 miR-520f-520c, -377, -155 
74,79
 
PR
-
 miR-520g, -527-518a, -182,  -10b, -375, -21 
74,77,78
 
HER2 status  
HER2
+
 miR-520d, -376b, -146a-5p, -375 
74,80
 
HER2
-
 miR-181c, -122 
74,78
 
Circulating miRNAS are represented in bold. 
Circulating miRNAs were also found to correlate with ER, PR and HER2 status in several 
studies. For example, higher levels of circulating miR-182 77, miR-21 and miR-10b 58 have 
been correlated with ER/PR- tumors. Furthermore, miR-155 expression levels were higher 
in sera of women with hormone-sensitive BCs 79. Moreover, higher levels of circulating 
miR-375 were associated with ER/PR- and HER2+ tumors, whereas higher levels of 
circulating miR-122 associated with HER2- tumors 78.  
Several specific miRNA expression profiles have also been associated with BC molecular 
subtypes. Iorio et al. identified a distinct miRNA signature in luminal BC, with 
overexpression of miR-191 and miR-26 and downregulation of miR-206 57. Likewise, 
miRNAs might differentiate between basal and luminal tumor subtypes in an independent 
data set 81. In an attempt to capture the heterogeneity of Luminal A and Luminal B BCs, 
Endo et al. compared the expression profiles of miRNAs in ER+ tissues between 
ERhigh/Ki67low tumors and ERlow/Ki67high tumors 82. They found that six miRNAs (let-7a, 
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miR-15a, miR-26a, miR-34a, miR-193b and miR-342-3p) were upregulated and a single 
miRNA was downregulated (miR-1290) in ERhigh/Ki67low tumors 82. 
Prognostic biomarkers 
MiRNAs have been correlated with clinical and pathological features that associate with 
prognosis in different tumor types and subgroups of BC patients 83,84. The search for 
prognostic biomarkers is a continuous and fundamental work in progress, since patients at 
higher risk may require differential therapeutic interventions.  
One of the main reasons for the BC associated mortality is metastization 85, a complex 
process that allows the primary tumor cells to spread to the neighboring as well as to 
distant parts of the organism. MiRNAs appear to be involved in the phenotypic changes 
associated with metastasis formation, such as epithelial-mesenchymal transition, as well 
as with the presence of circulating tumor cells, which correlate with metastatic spread 86. 
MiRNAs may act either as promotors of BC metastasis or as metastasis suppressors. 
Metastasis promoters include miR-9 87, miR-10b 55,88, miR-21 89, miR-29a 90, miR-155 91, 
miR-520c 92, miR-373 88,92, miR-214 93, miR-301 94 and miR-548j 95, whereas metastasis 
suppressors include  miR-17/20 96, miR-126 97, miR-193b 98, miR-206 99, miR-335 100, miR-
448 101, miR-601 102, miR-138 103, miR-515-5p 104, miR-203 105, miR-200 family and miR-
205 106. These specific miRNAs might serve as valuable biomarkers for predicting 
metastasis and tumor recurrence, which determine the unfavorable prognosis of BC 
patients. All these miRNAs were validated in tumor tissues and/or bodily fluids from BC 
patients and are depicted in Figure 2.  
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Figure 2. MiRNAs and breast cancer metastasis. MiRNAs are crucial in metastatic spreading, acting either 
as oncogenes, typically up-regulated, or as tumor suppressor genes, typically down-regulated. Circulating 
(red), non-circulating miRNAs and examples of targets. Abbreviations: miR – microRNA; CD - cluster of 
differentiation; ZEB - Zinc Finger E-Box Binding Homeobox 1; MMPs - Matrix metalloproteinases; VIM – 
vimentin; CDH1 – Cadherin 1.  
MiRNAs have also been associated with other clinical and pathological features that 
influence BC patients’ prognosis. MiR-21, aside from being a driver of metastasis, has 
been known to create a pro-tumorigenic environment by targeting numerous tumor 
suppressor genes, and its overexpression was correlated with advanced tumor stage and 
poor OS and DFS in BC patients 107,108. Several studies have independently associated 
miR-210 with BC development and its expression levels were correlated with tumor 
aggressiveness and poor prognosis 109,110. Moreover, some miRNAs have been associated 
with a good prognosis, such as the miR-30 family, that has been identified as an individual 
favorable prognostic marker in several studies 111-113. Other miRNAs, particularly 
downregulation of the miR-200 family, have also been associated with BC stem cells 114, 
one of the main obstacles for effective treatment of BC 115.  
Some studies have focused on particular subtypes of BC. Bailey et al. evaluated miRNAs 
expression in ER+ BC tissues and found that a cluster comprising let-7c and miR-125b was 
uniformly low in luminal B and lost in a subset of luminal A patients with worse OS, 
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indicating its potential as biomarker of good outcome in ER+ luminal A BC patients 116. 
Gasparini and co-workers  identified a 4-microRNA signature in triple negative BC that 
allowed for the stratification of those patients into high- and low-risk groups 117. Up-
regulation of miR-493 and miR-155 correlated with better patient outcome, whereas miR-
30e and miR-27a downregulation correlated with worse outcome 117. 
Interestingly, some miRNAs may differentially influence outcome depending on the 
characteristics of the tumors. Tuomarila et al. reported that high miR-200c expression 
independently predicted poor OS in patients with PR- tumors, whereas low expression 
independently predicted poor OS in patients with PR+ tumors 118. 
These and other miRNA signatures or single miRNAs that have been associated with 
prognosis are summarized in Table 3. 
Predictive biomarkers 
The role of miRNAs as potential predictive biomarkers is also a field of growing interest. 
When investigating the regulation of miRNAs expression by antiestrogen therapies in 
human BC specimens using the initial biopsy and comparing it with the surgery specimen 
after neoadjuvant ET, Maillot and co-workers 146 noticed that some miRNAs that were 
previously shown overexpressed in tamoxifen-resistant cell lines were up-regulated 
following ET. These results highlight the utility of considering miRNA expression in 
understanding ET resistance in BC. Other studies have searched for miRNAs able to 
predict therapeutic response of BC patients to ET. For instance, Rodriguez-Gonzalez and 
colleagues 147 have found that miR-30c independently predicted clinical benefit of 
tamoxifen therapy in patients with advanced BC. On the other hand, Rothe et al. 110 found 
that miR-210 high level expressions were associated with a higher risk of recurrence in 
tamoxifen treated patients. 
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Table 3. MiRNA panels or single miRNAs proposed with a prognostic aim. 
In addition to ET, miRNAs have been involved in responsiveness to other therapies. For 
instance, high circulating levels of miR-210 have been associated with resistance to anti-
HER2 therapy using trastuzumab 148 and miR-100 expression has been positively 
 miRNA Biological sample Consequences Refs. 
m
iR
N
A
s
 a
s
s
o
c
ia
te
d
 w
it
h
 p
o
s
it
iv
e
 o
u
tc
o
m
e
 
miR-100 
Tumor tissues 
↑
 
OS 
119
 
miR-29c 
120
 
miR-181d, -195-5p 
80
 
miR-128 
121
 
Let-7b, miR-205 
↑ RFS, OS 
122
 
miR-342-5p 
123
 
miR-497 ↓
 
TNM, LNM 
124
 
miR-133a ↑ RFS 125 
miR-30 family 
↑ OS, RFS, DFS  
↓Metastasis 
111-113
 
miR-206 ↑OS ↓TNM, LNM 126 
miR-601 ↓Metastasis ↑MFS 102 
miR-124 ↑ OS ↓TNM, LNM 127 
miR-138 ↓TNM, LNM 103 
miR-190b ↑MFS, OS 75 
miR-200b ↓ LNM 128 
miR-29b 
↑ DFS, OS 
129
 
miR-27a 
130
 
miR-374b-5p, -218-5p,  
-126-3p TNBC tissues 
↑DFS, OS 131 
miR-155 -493 ↑ OS 117 
let-7c, miR-99a, -125b Luminal A BC tissues ↑ OS 
116
 
 
m
iR
N
A
s
 a
s
s
o
c
ia
te
d
 w
it
h
 n
e
g
a
ti
v
e
 o
u
tc
o
m
e
 
miR-21 
Tumor tissues 
↑ Grade, TNM, LNM, metastasis 
↓DFS, RFS, OS 
107,108
 
miR-210 ↓OS, RFS, DFS, MFS ↑Grade 109 
miR-23a ↓RFS 66 
miR-423 ↑Metastasis 132 
miR-9 ↑ Grade, metastasis, LR 87 
miR-187 ↓ DSS, RFS 133 
miR-155 ↑TNM, grade, LNM ↓OS 134 
miR-221/222 ↓ MFS 135 
miR-421, -486, -503, -720,  
-1303 
↓MFS 
136
 
miR-375 ↑LR 137 
miR-548 family ↑ LNM ↓MFS 95 
miR-146a-5p ↓OS 80 
miR-27b-3p 
TNBC tissues 
 
↑ Metastasis ↓DSS 138 
miR-93 ↑ LNM, TNM, grade, Ki-67 139 
miR-21, -210, -221 
↓DFS, OS 
140
 
miR-34b 
141
 
miR-18b, -103, -107, -652 TNBC patients serum ↓ OS, RFS. 
142
 
miR-200b BC patients plasma ↓PFS, OS 
86
 
miR-202 
BC patients serum 
↓OS 143 
miR-10b-5p ↑TNM, grade, LNM 144 
miR-122 ↓MFS, RFS 78 
miR-10b, -34a, -155 ↑Metastasis 145 
↑ 
Incresead; 
↓ 
Decreased
 
Abbreviations:
 
RFS - Relapse-free survival; TNM - TNM Classification of Malignant Tumours; MFS - 
Metastasis-free survival; LR - Local recurrence; DSS - Disease-specific survival. 
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correlated with sensitivity to chemotherapy using paclitaxel 119. The potential role of 
miRNAs in the prediction of the response to these and other therapies, such as 
radiotherapy, are summarized in Table 4. 
Table 4. MiRNAs involved in therapeutic response (sensitivity/resistance) in BC. 
Therapies 
Role in 
response 
miRNA 
Putative 
targets 
Agent Biological samples Refs. 
H
o
rm
o
n
e
 t
h
e
ra
p
y
 
A
n
ti
e
s
tr
o
g
e
n
s
 
Sensitivity 
miR-342 CCNB1 
Tamoxifen 
Cell lines and tumor 
tissues 
149
 
miR-26a EZH2 
Tumor tissues 
150
 
miR-30c EGFR 
147
 
miR-10, 
-126 
- 
151
 
 
Resistance 
miR-
221/222 
CDKN1B 
Tamoxifen, 
fulvestrant 
Tumor tissues and 
cell lines 
152,153
 
miR-519a 
CDKN1B 
PTEN, 
RB1 
Tamoxifen 
Tumor tissues and 
cell lines 
154
 
miR-155 SOCS6 
131
 
miR-210 - Tumor tissues 
110
 
miR-301 
FOXF2, 
BBC3, 
PTEN, 
COL2A1 
Tumor tissues, cell 
lines and xenografts 
94
 
 
Aromatase 
inhibitors 
Sensitivity 
miR-125b 
let-7c 
ERBB2 
Letrozole, 
anastrozole 
Tumor tissues and 
cell lines 
116
 
 
Resistance miR-181a BCL2L11 Letrozole 
Cell lines, xenografts 
and tumor tissues 
155
 
 
Antibodies 
Sensitivity miR-210 - Trastuzumab Cell lines and plasma 
148
 
 
Resistance miR-21 PTEN Trastuzumab 
Cell lines, xenograft 
and tumor tissues 
156
 
 
Chemotherapy 
Sensitivity 
miR-451 MRP-1 
Doxorubicin 
Cell lines and tumor 
tissues 
157
 
miR-200c MRP-1 
158
 
miR-134 ABCC1 
159
 
miR-128 
BMI1, 
ABCC5 
Doxorubicin, 
Paclitaxel 
Cell lines, xenografts 
and tumor tissues 
121
 
miR-100 MTOR 
Paclitaxel 
Cell lines, xenografts 
and luminal tumor 
tissues 
119
 
miR-16 IKBKB 
Cell lines and tumor 
tissues 
160
 
miR-621 FBXO11 
Paclitaxel 
+Carboplatin 
Cell lines, xenografts 
and tumor tissues 
161
 
 
Resistance 
miR-125b 
BAK1, 
E2F3 
FEC 
Cell lines, tumor 
tissues and serum 
162
 
miR-141 - Taxane, 
Anthracyclines 
Cell lines and tumor 
tissues 
163
 
miR-221 CDKN1B Plasma 
164
 
miR-155 FOXO3a 
Paclitaxel, VP-
16, 
Doxorubicin 
Cell lines and tumor 
tissues 
165
 
 
Radiotherapy Sensitivity miR-155 RAD51 - 
Cell lines and TNBC 
tissues 
166
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Abbreviations: CCNB1 - Cyclin B1; EZH2 - Enhancer of zeste homolog 2; EGFR - epidermal growth factor 
receptor; CDKN1B - Cyclin-Dependent Kinase Inhibitor 1B; PTEN - phosphatase and tensin homolog; RB1 – 
retinoblastoma 1; SOCS6 - suppressor of cytokine signaling 6; FOXF2 - forkhead box F2; BBC3- BCL2 binding 
component 3; COL2A1 - collagen type II alpha 1; ERBB2 - Erb-B2 Receptor Tyrosine Kinase 2; BCL2L11 - 
Bcl-2-like protein 11; MRP1 - Multidrug resistance-associated protein 1; ABCC1 - ATP binding cassette 
subfamily C member 1; BMI1 - Bmi1 polycomb ring finger oncogene; ABCC5 - ATP binding cassette subfamily 
C member 5; MTOR - mechanistic target of rapamycin; IKBKB - IκB kinase β; FBXO11 - F-box protein 11; 
BAK1 - BCL2 antagonist/killer 1; E3F3 - E2F transcription factor 3; FOXO3a - Forkhead box O3a; RAD51 - 
RAD51 recombinase; FEC - 5-Florouracil, Epirubucin and Cyclophosphamide. 
Several clinical trials, summarized in Table 5, are currently ongoing to address the role of 
miRNAs in diagnosis, prognosis and prediction of response to therapy, aiming at the 
translation of current knowledge on miRNAs in BC into clinical practice. 
Table 5. Ongoing clinical trials aiming at the introduction of miRNAs in clinical practice. 
Clinical trial Patient population Intervention Aims 
Study 
start date 
NCT00581750 
Observational 
Patients with lobular carcinoma in situ Tumor profiling Diagnosis 
October 
2001 
NCT01231386 
Observational 
Patients undergoing neoadjuvant or adjuvant 
chemotherapy and HT for locally advanced & 
inflammatory BC 
Tumor profiling 
Circulating 
miRNAs 
Prognosis 
Drug 
sensitivity 
October 
2014 
NCT01722851 
Observational 
Newly diagnosed BC patients who are 
scheduled to undergo neoadjuvant 
chemotherapy/HT and patients who present 
with disease recurrence or disease 
progression, and who are commenced on 
systemic therapies (HT and/or 
chemotherapy) 
Circulating 
miRNAs 
 
Prognosis 
Drug 
sensitivity 
September 
2013 
NCT02656589 
Observational 
Patients with HER2
+
 advanced stage BC 
who were treated with Herceptin 
Drug 
sensitivity 
June 2015 
NCT01598285 
Observational 
Patients suffering from metastatic BC, 
treated with bevacizumab 
May 2012 
NCT01612871 
Observational 
Patients with metastatic invasive BC or 
locally advanced BC for which treatment with 
tamoxifen or anti-aromatase is indicated 
June 2012 
CONCLUSION 
BC is a very heterogeneous disease, and several biological features are routinely used for 
diagnostic, prognostic and predictive purposes, including histological grade, lymph node 
status, hormone receptor status, and HER2 status. These factors have been associated 
with BC patient’s survival and clinical outcome following treatment. Nevertheless, some 
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patients with similar combination of those features follow different clinical paths, 
demonstrating that the capacity of determining prognosis and predicting therapeutic 
outcome in BC patients remains limited. Several mRNA-based tests are currently available 
with the aim of improving BC prognostication, but its use in clinical practice is still limited. 
New biomarkers are therefore needed to assist in improving BC patient prognostication 
and monitoring, allowing for a more precise definition of the therapeutic and follow-up 
strategy in an individual basis.  
Based on the studies cited in this review, it is remarkable that ncRNAs are adding an extra 
dimension to the understanding of BC biology. MiRNAs, in particular, are emerging as 
promising biomarkers for BC diagnosis (e.g. miR-155 and miR-195), prognosis (e.g. miR-
29b and miR-30 family) and prediction of response to therapy (e.g. miR-30c and miR-221). 
It should be emphasized that miRNAs are easily accessible, affordable, non-invasive tools 
for personalized management of BC patients, since they circulate stably in bodily fluids. 
These features allow miRNAs to respond to current clinical needs and provide the 
opportunity to bypass the problems associated with tumor tissue biopsy. Although some 
lncRNAs have also shown potential to serve as BC biomarkers, the stability and origin of 
circulating lncRNAs remain largely unknown, and additional studies are required to support 
a definitive clinical application. Regarding tRNAs, many questions also remain 
unanswered, such as the origin and its physiological role. 
When reviewing the data from several studies, widespread inconsistencies across them 
are found. The cause might be attributable to differences in sample type, with some 
studies using plasma or serum and other using whole blood, differences in technology 
platforms used for miRNA profiling, such as next-generation sequencing (NGS) or real 
time reverse transcription polymerase chain reaction, differences in the choice of pre- or –
post-operative samples, as well as from the choice of different genes for data 
normalization. These discrepancies among reported signatures highlight the need to 
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standardize experimental conditions for circulating miRNAs studies, as well as the need to 
validate these findings in additional independent cohorts as well as preclinical/clinical 
verification studies, before the clinical utility of circulating miRNAs may be established.  
In conclusion, the emergence of ncRNA classes as possible BC biomarkers, mainly 
miRNAs, shows great potential to foster precision medicine in BC, although its application 
in clinical routine is still a long term goal. 
Abbrevations: 
BC – breast cancer 
BCAR4 - BC anti-estrogen resistance 4  
CCAT2 - lncRNA colon cancer associated transcript 2  
CMF - Cyclophosphamide, Methotrexate and Fluorouracil  
DFS – disease-free survival 
EGOT - eosinophil granule ontogeny transcript 
ER – estrogen receptor 
PR – progesterone receptor 
HER2 - human epidermal growth factor receptor 2 
ET – endrocrine therapy 
HOTAIR - HOX transcript antisense RNA  
HT – Hormone-therapies 
LincRNAs - long intergenic non-coding RNAs  
lncRNAs – long noncoding RNAs 
LNM - lymph node metastasis 
MALAT1 - metastasis-associated lung adenocarcinoma transcript 1 
MiRNAs – microRNAs 
mRNA – messenger RNA 
NBAT1 - neuroblastoma associated transcript 1  
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ncRNAs – noncoding RNAs 
OncomiRs - oncogenic miRNAs 
OS – overall survival 
PFS - progression free-survival 
PTPRG-AS1- PTPRG antisense RNA 1  
ROR - Regulator of Reprogramming 
rRNAs - ribosomal RNAs 
SPRY4-IT1 - SPRY4 intronic transcript 1  
SNHG17 - small nucleolar RNA host gene 17  
snoRNAs - small nucleolar RNAs 
tRNAs – transfer RNAs 
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Appendix VI. MiRNAs with fold variation values higher than 1 in the global expression assay. 
LumA Rec vs. LumA NRec LumB Rec vs. LumB NRec Lum Rec vs. Lum NRec 
microRNA 
Fold 
Change 
microRNA 
Fold 
Change 
microRNA 
Fold 
Change 
miR-196a-5p 
2
 2,1281 miR-9-5p
 1
 2,5978 miR-9-5p 
1
 1,4448 
miR-181b-5p -1,0119 miR-210-3p 
1
 1,7178 miR-149-3p 
1
 1,23995 
miR-130a-3p 
1
 -1,0519 miR-182-5p 
2
 1,6028 miR-126-3p -1,0909 
miR-29b-3p -1,1169 miR-7-5p 
1
 1,3978 miR-1 -1,1352 
let-7b-5p -1,1269 miR-200c-3p 1,2778 miR-148a-3p -1,1419 
let-7i-5p -1,1369 miR-31-5p 
1
 1,0928 miR-30d-5p -1,2139 
miR-106b-5p -1,1419 miR-221-3p 1,0128 miR-181a-5p 
2
 -1,4322 
miR-132-3p 
1
 -1,1519 miR-125b-5p -1,0172 miR-200a-3p -1,5732 
miR-26b-5p -1,1619 miR-146a-5p -1,0372 miR-205-5p 
2
 -2,3252 
miR-19b-3p -1,1769 miR-181a-5p 
2
 -1,0622 
  
miR-192-5p 
1
 -1,1969 miR-205-5p 
2
 -1,1172 
  
let-7g-5p -1,2019 miR-1 
1
 -1,1472 
  
miR-16-5p -1,2319 miR-10b-5p -1,4022 
  
miR-15a-5p -1,2619 
    
miR-106a-5p -1,2669 
    
miR-20a-5p -1,2769 
    
let-7a-5p -1,3019 
    
miR-21-5p -1,3169 
    
miR-214-3p -1,3569 
    
miR-93-5p -1,4119 
    
let-7f-5p -1,4369 
    
miR-222-3p -1,4419 
    
miR-200c-3p -1,4719 
    
miR-155-5p -1,5119 
    
let-7e-5p -1,5119 
    
let-7d-5p -1,5619 
    
miR-148a-3p -1,6369 
    
miR-181a-5p 
2
 -1,6519 
    
miR-23b-3p -1,7569 
    
miR-23a-3p -1,8069 
    
miR-19a-3p -1,8519 
    
miR-1 
1
 -1,8869 
    
miR-221-3p -1,9319 
    
miR-195-5p -1,9369 
    
miR-18a-5p 
1
 -1,9919 
    
miR-30c-5p 
2
 -2,0419 
    
miR-182-5p 
2
 -2,1119 
    
miR-186-5p 
1
 -2,1319 
    
miR-141-3p -2,1619 
    
miR-17-5p 
1
 -2,1919 
    
miR-30d-5p -2,2769 
    
miR-30b-5p 
2
 -2,4819 
    
miR-101-3p -2,5319 
    
miR-200b-3p 
2
 -3,0019 
    
miR-92b-3p 
1
 -3,1069 
    
miR-200a-3p -3,2169 
    
miR-205-5p 
2
 -4,1269 
    1
 Cps higher than 30 
2
 miRNAs chosen for further validation 
Abbreviations: Lum – Luminal; Rec – Recurrent. 
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Appendix VII. Univariable cox regression models assessing the association between 
clinicopathological features and clinical outcome. 
Model Outcome Variable HR (95% CI) p-value 
Univariable 
Analysis 
ERFS 
HER2 status 
Negative 
-
 
Positive 
 
1 
3.459 (1.352-8.851) 
0.010 
Ki-67 index 
<15% 
>15% 
 
1 
5.823 (2.254-
15.042) 
<0.001 
Molecular 
subtype 
Luminal A 
Luminal B 
 
1 
5.109 (1.511-
17.271) 
0.009 
Grade 
G1&G2 
G3 
 
1 
2.689 (1.114-6.492) 
0.028 
DFS 
HER2 status 
Negative 
-
 
Positive 
 
1 
3.325 (1.570-7.041) 
0.002 
Ki-67 index 
<15% 
>15% 
 
1 
2.475 (1.243-4.926) 
0.010 
Grade 
G1&G2 
G3 
 
1 
2.208 (1.156-4.218) 
0.016 
DMFS 
HER2 status 
Negative 
-
 
Positive 
3.856 (1.796-8.278) 0.001 
Ki-67 index 
<15% 
>15% 
2.271 (1.090-4.734) 0.029 
Grade 
G1&G2 
G3 
2.247 (1.133-4.456) 0.020 
Abbreviations: ERFS – endocrine resistance-free survival; DFS – disease-free survival; 
DMFS – distant metastasis-free survival; HER2 – human epidermal growth factor 2 receptor; 
G – grade; HR – Hazard ratio; CI – confidence interval. 
 
